

# GLOBAL JOURNAL

OF MEDICAL RESEARCH: F

## Diseases Cancer, Ophthalmology & Pediatric



Dystrophy and Vulva Cancer

Murray-Jackson-Lawler Syndrome

Highlights

Awareness Regarding Diabetes

Functional Dietary Supplementation

Discovering Thoughts, Inventing Future

VOLUME 19    ISSUE 5    VERSION 1.0



GLOBAL JOURNAL OF MEDICAL RESEARCH: F  
DISEASES  
CANCER, OPHTHALMOLOGY & PEDIATRIC

---



GLOBAL JOURNAL OF MEDICAL RESEARCH: F  
DISEASES  
CANCER, OPHTHALMOLOGY & PEDIATRIC  
VOLUME 19 ISSUE 5 (VER. 1.0)

---

OPEN ASSOCIATION OF RESEARCH SOCIETY

© Global Journal of Medical Research. 2019.

All rights reserved.

This is a special issue published in version 1.0 of "Global Journal of Medical Research." By Global Journals Inc.

All articles are open access articles distributed under "Global Journal of Medical Research"

Reading License, which permits restricted use. Entire contents are copyright by of "Global Journal of Medical Research" unless otherwise noted on specific articles.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission.

The opinions and statements made in this book are those of the authors concerned. Ultraculture has not verified and neither confirms nor denies any of the foregoing and no warranty or fitness is implied.

Engage with the contents herein at your own risk.

The use of this journal, and the terms and conditions for our providing information, is governed by our Disclaimer, Terms and Conditions and Privacy Policy given on our website <http://globaljournals.us/terms-and-condition/menu-id-1463/>

By referring / using / reading / any type of association / referencing this journal, this signifies and you acknowledge that you have read them and that you accept and will be bound by the terms thereof.

All information, journals, this journal, activities undertaken, materials, services and our website, terms and conditions, privacy policy, and this journal is subject to change anytime without any prior notice.

Incorporation No.: 0423089  
License No.: 42125/022010/1186  
Registration No.: 430374  
Import-Export Code: 1109007027  
Employer Identification Number (EIN):  
USA Tax ID: 98-0673427

## Global Journals Inc.

(A Delaware USA Incorporation with "Good Standing"; Reg. Number: 0423089)

Sponsors: Open Association of Research Society

Open Scientific Standards

### Publisher's Headquarters office

Global Journals® Headquarters  
945th Concord Streets,  
Framingham Massachusetts Pin: 01701,  
United States of America

USA Toll Free: +001-888-839-7392

USA Toll Free Fax: +001-888-839-7392

### Offset Typesetting

Global Journals Incorporated  
2nd, Lansdowne, Lansdowne Rd., Croydon-Surrey,  
Pin: CR9 2ER, United Kingdom

### Packaging & Continental Dispatching

Global Journals Pvt Ltd  
E-3130 Sudama Nagar, Near Gopur Square,  
Indore, M.P., Pin:452009, India

### Find a correspondence nodal officer near you

To find nodal officer of your country, please  
email us at [local@globaljournals.org](mailto:local@globaljournals.org)

### eContacts

Press Inquiries: [press@globaljournals.org](mailto:press@globaljournals.org)  
Investor Inquiries: [investors@globaljournals.org](mailto:investors@globaljournals.org)  
Technical Support: [technology@globaljournals.org](mailto:technology@globaljournals.org)  
Media & Releases: [media@globaljournals.org](mailto:media@globaljournals.org)

### Pricing (Excluding Air Parcel Charges):

Yearly Subscription (Personal & Institutional)  
250 USD (B/W) & 350 USD (Color)



# EDITORIAL BOARD

GLOBAL JOURNAL OF MEDICAL RESEARCH

## *Dr. Jixin Zhong*

Department of Medicine, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210, United States

## *Rama Rao Ganga*

MBBS MS (University of Health Sciences, Vijayawada, India) MRCS (Royal College of Surgeons of Edinburgh, UK) United States

## *Dr. Feng Feng*

Boston University Microbiology 72 East Concord Street R702 Duke University, United States of America

## *Dr. Lisa Koodie*

Ph.D. in Pharmacology, University of Minnesota Medical School, Minnesota, United States

## *Dr. Krishna M Vukoti*

Ph.D in Biochemistry, M.Tech in Biotechnology, B.S in Pharmacy, Case Western Reserve University, United States

## *Dr. Xingnan Li*

Ph.D in Cell Biology, B.S in Molecular Biology, Stanford University, United States

## *Dr. Michael Wink*

Ph.D., Technical University Braunschweig, Germany  
Head of Department Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany

## *Dr. Han-Xiang Deng*

MD., Ph.D. Associate Professor and Research Department Division of Neuromuscular, Medicine Davee Department of Neurology and Clinical Neurosciences Northwestern, University Feinberg School of Medicine, United States

## *Dr. Roberto Sanchez*

Associate Professor Department of Structural and Chemical Biology Mount Sinai School of Medicine Ph.D., The Rockefeller University, United States

## *Dr. William Chi-shing Cho*

Ph.D., Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong

## *Dr. Yash Kapadia*

Doctor of Dental Surgery, University of Louisville School of Dentistry, United States

## *Dr. Guodong Niu*

Ph.D. in Entomology, M.S. in Microbiology, B.S. in Environmental Science, The Pennsylvania State University, University Park, PA, United States

## *Dr. Arpita Myles*

Ph.D, M.Sc. in Biotechnology, B.Sc in Microbiology, Botany and Chemistry, United States

## *Dr. Wael Ibrahim Abdo Aikhiary*

Ph.d, M.Sc in Clinical Pathology, MBBCH, M.D in Medicine, Mansoura University, Faculty of Medicine, Egypt

*Dr. Izzet Yavuz*

Ph.D, M.Sc, D Ped Dent. Associate Professor, Pediatric Dentistry Faculty of Dentistry, University of Dicle, Turkey

*Dr. Rabiatal Basria SMN Mydin*

Ph.D in Cancer Genetics, BSC (HONS) in Biotechnology, University of Science Malaysia, Malaysia

*Dr. (Mrs.) Sunanda Sharma*

Ph.D, M.V.Sc., AH, M.V.Sc in Animal Reproduction, Veterinary Obstetrics and Gynaecology, College of Veterinary & Animal Science, Rajasthan Agricultural University, Bikaner, India

*Dr. Subhadra Nandakumar*

Ph.D., M.Sc in Applied Microbiology, B.Sc in Microbiology, University of Madras, India

*Sanguansak Rerksuppaphol*

Department of Pediatrics Faculty of Medicine Srinakharinwirot University NakornNayok, Thailand

*Antonio Simone Lagan*

M.D. Unit of Gynecology and Obstetrics Department of Human Pathology in Adulthood and Childhood “G. Barresi” University of Messina, Italy

*Dr. Pejic Ana*

Assistant Medical Faculty Department of Periodontology, and Oral Medicine University of Nis, Serbia

*Dr. Sunil Sirohi*

B.Pharm in Pharmaceutical Sciences, MS in Pharmacology, Ph.D in Pharmacology, Washington State University, Pullman, WA, United States

*Dr. Tsvetelina Velikova*

Ph.D, MD in Clinical Immunology, Medical University of Sofia Sofia University, Bulgaria

*Dr. M. Alagar Raja*

Ph.D in Pharmaceutical Sciences, M.Pharmacy in Pharmaceutical Analysis, B.Pharmacy S. Chattanatha Karayalar College of Pharmacy, Nalanda Collge of Pharmacy Tenkasi, Tamil Nadu, India

*Dr. Osama Hasan Alali*

Ph.D, Master's Degree, Postgraduate Diploma in Orthodontics, Dentistry, Department of Orthodontics, University of Aleppo Dental School Aleppo, Syria

*Dr. Sultan Sherif Dhastagir*

Ph.D, M.Sc in Medical Biochemistry, Faculty of Medicine, Garyounis/Benghazi University, Libya

*Dr. Seung-Yup Ku*

M.D., Ph.D., Seoul National University Medical College, Seoul, Korea Department of Obstetrics and Gynecology Seoul National University Hospital, Seoul, Korea

*Dr. Ivandro Soares Monteiro*

M.Sc., Ph.D. in Psychology Clinic, Professor University of Minho, Portugal

*Dr. Pina C. Sanelli*

Associate Professor of Radiology Associate Professor of Public Health Weill Cornell Medical College Associate Attending Radiologist NewYork-Presbyterian Hospital MRI, MRA, CT, and CTA Neuroradiology and Diagnostic Radiology M.D., State University of New York

*Dr. Alfio Ferlito*

Professor Department of Surgical Sciences University of Udine School of Medicine, Italy

*Dr. Michael R. Rudnick*

M.D., FACP Associate Professor of Medicine Chief, Renal-Electrolyte and Hypertension Division (PMC) Penn Medicine, University of Pennsylvania Presbyterian Medical Center, Philadelphia Nephrology and Internal Medicine Certified by the American Board of Int, United States

*Dr. Rajeev Vats*

Ph.D., M.Sc., B.Sc in Zoology, M.Phil in Bioinformatics, PGDCA, The University of Dodoma, Tanzania

## CONTENTS OF THE ISSUE

---

- i. Copyright Notice
  - ii. Editorial Board Members
  - iii. Chief Author and Dean
  - iv. Contents of the Issue
- 
1. Search of Ways to Improve the Efficiency of the Diagnostic Results and the Quality of Treatment of Dystrophy and Vulva Cancer. ***1-5***
  2. Murray-Jackson-Lawler Syndrome. ***7-10***
  3. Association between Body Mass Index and Diabetic Complications among Type-2 Diabetic Patients in Semi-Urban Area, Bangladesh. ***11-15***
  4. Functional Dietary Supplementation of Okara (Soybeans Residue) on Streptozotocin Induced Diabetes Mellitus in Male Wistar Rats ***17-28***
- 
- v. Fellows
  - vi. Auxiliary Memberships
  - vii. Preferred Author Guidelines
  - viii. Index





# Search of Ways to Improve the Efficiency of the Diagnostic Results and the Quality of Treatment of Dystrophy and Vulva Cancer

By Cherenkov V. G., Sannikova M. V., Alexandrova I. V., Pacewicz K. G K. G. Pacwicz & Egorova E. S.

*Jaroslav-the- Wise Novgorod State University*

**Abstract-** With vulvar dysplasia, sclerotic deprive and suspected cancer under our observation there were respectively 115 and 97 patients. The effectiveness of treatment of vulva dystrophy (VIN II-III degree) by the method of photodynamic therapy (PDT) 45.8=4.7%. However, dysplasia II - III degree, sclerotic changes with the formation of pronounced horn scales prevents the full PDF and recurrence of the disease. Therefore, the treatment of choice is surgical treatment with a reconstructive plastic. In order to reduce bleeding and antitlastic we used krioapplicatsiya, apparate "Harmonics", and the decay of tumor angiographic chemoembolization before surgery. The use of new reconstructive plastic surgery, including with the use of abdominal skin and fascial flap combined with vascularized lower segments of the rectus muscles (*patent for invention № 2580665 from 11.11.14*), have helped to reduce complications, improve cosmetic effect and reduce the duration of lymphorrhea in 2-3 days.

**Keywords:** *vulvar cancer, PDT, cryoapplication, apparate "Harmonics", angiohemoembolization, reconstructive plastic surgery of the abdominal skin and lower segments of the rectus muscles.*

**GJMR-F Classification:** *NLMC Code: WB 141*



*Strictly as per the compliance and regulations of:*



# Search of Ways to Improve the Efficiency of the Diagnostic Results and the Quality of Treatment of Dystrophy and Vulva Cancer

Cherenkov V. G. <sup>α</sup>, Sannikova M. V. <sup>σ</sup>, Alexandrova I. V. <sup>ρ</sup>, Pacewicz K. G. K. G. Pacwicz <sup>ω</sup> & Egorova E. S. <sup>¥</sup>

**Abstract-** With vulvar dysplasia, sclerotic deprive and suspected cancer under our observation there were respectively 115 and 97 patients. The effectiveness of treatment of vulva dystrophy (VIN II-III degree) by the method of photodynamic therapy (PDT) 45.8=4.7%. However, dysplasia II - III degree, sclerotic changes with the formation of pronounced horn scales prevents the full PDF and recurrence of the disease. Therefore, the treatment of choice is surgical treatment with a reconstructive plastic. In order to reduce bleeding and antiblastic we used krioapplikatsiya, apparatus "Harmonics", and the decay of tumor angiographic chemoembolization before surgery. The use of new reconstructive plastic surgery, including with the use of abdominal skin and fascial flap combined with vascularized lower segments of the rectus muscles (*patent for invention № 2580665 from 11.11.14*), have helped to reduce complications, improve cosmetic effect and reduce the duration of lymphorrhea in 2-3 days.

**Keywords:** vulvar cancer, PDT, cryoapplication, apparatus "Harmonics", angiochemoembolization, reconstructive plastic surgery of the abdominal skin and lower segments of the rectus muscles.

## I. INTRODUCTION

Cancer of the external genitals is up to 8 % in the overall structure of the incidence of malignant neoplasms of female genital organs, relapses that occur within the first 5 years to 60 %. [1]. Vulva cancer (CV) is mainly detected in elderly menopausal women. Unfortunately, it is increasingly common at a younger age, associated with the increasing threat of papillomavirus infection [2]. And this is a reality that we have to reckon with. Features of development, multicentricity, and often diffusivity of the lesion against the background of diffuse dysplastic changes and sclerotic lichen or papillomatosis create certain difficulties in the early stages of diagnosis [8]. Given the above, we used the technique of scraping with a scalpel consisting of two stages: 1) removal (scraping) Horny scales of the epithelium of the 4-5 most suspicious areas; 2) scarification and obtaining cells from deep layers within the basal layer before the appearance of "dews" blood. Cytological examination of vulvar dysplasia allowed at 76.0±3.4% of cases to establish a

correct diagnosis, including 13 cases against this background, the identified cancer (0-1 stages, which is significantly higher than the cumulative literature data (up to 57%) [3]. The study of methods of reconstructive plastic surgery (RPO) with a skin-fascial flap from the posterior thigh was started in the 80s years last century by Knapstein P. G [9].

The possibilities of treatment of vulvar dysplasia and cancer are contradictory.

## II. AIM

Assessment and the role of the VDT and the search of ways of increase of efficiency of diagnostics and surgical procedures in complex therapy of vulvar dystrophies and vulvar cancer.

## III. MATERIAL AND METHODS

With vulvar dysplasia and sclerotic lichen under our supervision were 115 patients aged 46 to 82 years and 9 patients in combination with carcinoma in situ and RV 1-II stages. Mean age 55±3.6%. PDT was performed in 43 patients with diffuse vulvar dysplasia, incl. (VIN I - 27, VIN II - 16) and in RV in order to prepare the surrounding tissues (in the transition of sclerotic changes) on the skin of inguinal masonry and inner thighs), incl. in 2 patients with relapse of CV.

Author <sup>α</sup> <sup>σ</sup> <sup>ρ</sup> <sup>ω</sup> <sup>¥</sup>: Jaroslav-the- Wise Novgorod State University, regional clinical Oncology center. Veliky Novgorod.  
e-mail: v.g.cherenkov@yandex.ru




Fig. 1: The incidence of CV diseases per 100 000 of the female population of the region by age groups on average for the last 5 years (2014-2018).

In our study we used a second generation sensitizer – photodiazine. PDT session was performed 1.5-2 hours after intravenous drip infusion of the drug (VETA-Grand LLC) at the rate of an average of 1.0 mg/kg body weight in 100 ml of 0.9% sodium chloride solution in a semi-darkened room. Laser irradiation using semiconductor device "Atkus - 2" with energy density of 80-250 j/cm<sup>2</sup> and exposure time from 10 to 30 min. PDT allowed to cure VIN I in 21(77.7=2.2%) and only in 2 of 16 (12.5=0.5%) women with VIN II degree.

However, after 5 years, the resumption of skin itching and residual focal leukoplakia were noted in 5 women, which is associated with insufficient exposure to laser exposure to each zone, in the presence of pronounced Horny scales. In addition, PDT by moving the laser beam by hand does not avoid subjectivity, and means of disease recurrence.

5-year relapse-free survival was found in 16 of 27 (59.2±3.6%) women with predominantly VIN I. In situations with diffuse or transient II - III degree dysplasia behind the femoral fold, in our opinion, a combined approach is required in the choice of treatment depending on the prevalence of the process (PDT+ vulvectomy with RPO).



Fig. 2: Cancer in situ on the background of diffuse sclerotic lichen and vulvar dysplasia, passing to the skin of the thigh (P., 62 years).

As note themselves women after PDT was only a temporary subjective effect, after which itching resumed and they resorted to various popular their means. Plasty with full-fledged skin-fascial flaps with good vascularization from the posterior-medial surface of the thigh in 97 patients showed that it is pathogenic, since one of the main reasons for the development of VIN I-III is the sclerosis of local vessels and tissue atrophy. All patients underwent expanded vulvectomy and bilateral or unilateral inguinal-femoral lymph node dissection depending on the results of ultrasound and MRI.

Despite the obliteration of arterial vessels in the formation of tabloid dystrophy, due to anatomical features in the area of the vulva is not only preserved, but also expanded venous plexus with outflow through V. pudendi interna. In order to avoid dispersion and devitalization of the tumor cells (ablasic and antiblastic)

excision always conducted radiowave scalpel and apparatus "Harmonics", making the preliminary incision of the skin usual scalpel.

Recently, the excision of the tumor in 37 women was preceded by cryoapplication and credibilitate to  $t - 185^{\circ}$  through the entire thickness of the tumor using the apparatus ERBE-6, exposure 5-10 min (Fig. 3). The

data show that this approach is promising and does not affect healing. Surgical excision is almost without bloodshed on the part of the tumor. In the latter group, within 5 years, relapses occurred only in 3 patients ( $8.1 \pm 0.9\%$ ), which is significantly lower than in the literature.



Fig. 3: Krioaplikatsiya and freezing the tumor.

In three patients with RV T3n2mo with tumor decay and bleeding, we undertook angiographic

chemoembolization (HAE) with the introduction of 30 mg doxorubicin (Fig. 4).



a)



b)

Fig. 4: Angiographic chemoembolization a. pudenda interna: (a) angiography to HAE; b) angiography after HAE).

And although the diameter of a. pudenda interna did not allow to hold the catheter to the focus of pathology. Partial HAE it possible to reduce bleeding, restore hemoglobin by additional hemotransfusion and perform expanded vulvectomy and bilateral lymph node dissection.






Fig. 5: (a) excision of the vulva and inguinal areas; (b) and (c) Pfannenstiel incision exposing the rectus muscles and (a) epigastrica inferior; (d) formation of the labia majora by cross-segments of the rectus muscles.

With the aim of forming the volume of the external genitalia, improve the appearance quality and reduce lymphorrhea recently we have developed a method rekonstruktivnoi plastics (Patent No. 2580665 [4]) of the external genitalia through the mobilization of abdominal skin and fascial flap and the lower segments of the rectus muscles along with a.epigastrica inferior (Fig 5 a, b, c and d) using the apparatus "Harmonics". Closure of the wound was carried out at the beginning cross mobilized segments of direct muscles of a stomach on the vascular pedicle. The latter create the missing volume of the labia majora and represent a unique plastic material for vascularization and lymph drainage. In the area of the intersection of muscles and ends of the segment, fixation to the muscles of the vagina was performed by dissolving seams so that they did not hang over the mouth of the urethra and did not close the symphysis of the pubis. The next stage was sutured fascia of the rectus muscles of the abdominal wall. Then, 6-7 stitches were applied along the Donati to the skin of the perineum and the back wall of the vagina without tension in order to determine to what level the skin defect will be filled with an abdominal skin-fascial flap without tension.

Abdominal skin-fascial flap was placed on the wound surface, adapting it by cutting off excess and sharp skin areas, sutures were applied. Determining the projection of the abdominal flap, adjacent to the pubis, imposes two provisory internal anchor sutures to the

periosteum, which is then stitched to the abdominal flap (without skin), genital forming a fold. Then through a separate puncture of the abdominal flap in the inguinal areas has introduced an active drainage in the inguinal-femoral area. Then every 0.8 cm for the tightness of stitches on the skin and the vaginal mucosa around the entire circumference and nodal skin sutures for Donati.

The operations were performed in 12 women, mostly aged 45-55 years with abdominal obesity. The process was localized on the skin and mucous membrane of the anterior half of the vulva. In one case, focal leukoplakia was an independent disease, in another case, an initial cancer was diagnosed. Healing took place by primary tension, except for 1 woman ( $8.3 \pm 1.4\%$ ) with obesity and type II diabetes mellitus. An important aspect of reconstructive vulvectomy by abdominal flap in combination with segments of straight muscles on the vascular pedicle was a decrease in the duration of lymphorrhea for 2-3 days and the formation of the appearance of the organ.

#### IV. DISCUSSION AND CONCLUSIONS

As a result of the work carried out, mortality from CV ( Fig. 6), despite the increase in morbidity, since 2005, when plastic surgery was introduced and modern approaches to tumor devitalization decreased by 6.2 times.




Fig. 6: Morbidity and mortality from cancer of the vulva (100 000 female population) in Novgorod region.

Thus, further ways to improve the results of treatment lie, on the one hand, on the application and improvement of modern technologies, in particular PDT, cryodevitalization, apparatus "Harmonics" and reconstructive plastic surgery, and on the other, to improve cancer literacy of the population and General practitioners.

The use of reconstructive plastic operations in particular with the use of vascularized lower the segments of the rectus abdominis muscle is an individual method choice in young women with cancer of the vulva and vulgar dystrophy (VIN II-III), a measure of prevention of invasive forms cancer, helps to reduce complications, increase cosmetic effect and reduce the duration of lymphorrhea on average for 3-4 days.

Requires further study of the possibilities of the use of angiohemoembolization in neoadjuvant mode.

10. Patent No. 2580665 for invention dated 11.11.14 g vniigpe. V. G. Cherenkov A. B., Egorova E. S., Shpenkov, A. A., Aleksandrova, M. S. Pilosov.

### LITERATURE

1. Nerodo G. A. Relapses of vulva cancer // Proceedings of the VI all-Russian Congress of oncologists, 2005, p. 382-383.
2. Cherenkov V. G., I. V. Alexandrov, E. S. Egorov. A rare case of vulva cancer in a young woman.// Tumors of the female reproductive system (mammology/oncogynecology), № 1-2, 2013, p. 24.
3. Cherenkov V. G., Sannikova M. V. Screening and treatment of risk groups and external genital cancer. LAP LAMBERT Academic Publishing, 2018, 58p.
4. Zharov, A. V., Vazhenin A. V. Optimization of treatment of patients with vulva cancer. Chelyabinsk, 2005, 131c.
5. Ate van der Zee. Modern treatment of vulva cancer. Topical issues of oncogynecology//Practical Oncology, vol. 10, № 2, 2009, p. 84-85.
6. Krikunova L. I., Kaplan M. A., Rykova E. V. the Role of photodynamic therapy in the treatment of vulva cancer// 1 international conference. Obrninsk, 1999.- p. 32-33.
7. Nerodo G. A. Complex treatment of patients with recurrence of vulvar cancer/ Scientific-practical conference with international participation "Improvement of medical care for cancer, including topical problems of pediatric Hematology and Oncology. The national cancer program."Yll Congress of oncologists of Russia, vol. 2, Moscow, 2009, pp. 61-62.8.
8. Urmancheyeva A. F. Epidemiology of cancer of the vulva. Risk and prognosis factors. Practical Oncology, vol. 7, № 4, 189-196, 2006.
9. Knapstein P. G. Erweiterte Behandlungsmöglichkeiten Vulvakarzinomas durch das Verfahren plastic reconstructive\ P. G. Knapstein, M. Mahlke, W. Poleska, W. Zeuner \ Zbl.Gynekol.-1985.- Bd.107, N 24.-p.1479-1487.





This page is intentionally left blank



GLOBAL JOURNAL OF MEDICAL RESEARCH: F  
DISEASES

Volume 19 Issue 5 Version 1.0 Year 2019

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Murray-Jackson-Lawler Syndrome

By Varsha Verma, Sumit Kar, Nidhi Yadav, Pooja Bonde, Pooja Manwar,  
Komal Ramteke & Safa Patrick

*Mahatma Gandhi Institute of Medical Sciences*

**Abstract-** Pachyonychia congenita (PC) is a rare autosomal dominant genodermatosis. It is of four types, type I due to mutation in genes 6a and 16, and 6b and 17 in type II. A 2 yr old male child presented in our OPD with hypertrophy of nails, hyperkeratotic papules over body, lusterless and sparse hair and natal teeth since childhood. Microscopy nail clippings and scrapping were done to rule out fungal infection. No evidence of any associated malignancy was found after thorough workup. He was diagnosed as PC Type 2. This case is being reported because of its rarity.

**Keywords:** *pachyonychia congenita, genodermatosis, autosomal dominant, subungual hyperkeratosis, hyperkeratotic papules.*

**GJMR-F Classification:** *NLMC Code: WR 20*



MURRAY-JACKSON-LAWLERSYNDROME

*Strictly as per the compliance and regulations of:*



© 2019. Varsha Verma, Sumit Kar, Nidhi Yadav, Pooja Bonde, Pooja Manwar, Komal Ramteke & Safa Patrick. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Murray-Jackson-Lawler Syndrome

Varsha Verma <sup>α</sup>, Sumit Kar <sup>σ</sup>, Nidhi Yadav <sup>ρ</sup>, Pooja Bonde <sup>ω</sup>, Pooja Manwar <sup>¥</sup>, Komal Ramteke <sup>§</sup>  
& Safa Patrick <sup>χ</sup>

**Abstract-** Pachyonychia congenita (PC) is a rare autosomal dominant genodermatosis. It is of four types, type I due to mutation in genes 6a and 16, and 6b and 17 in type II. A 2 yr old male child presented in our OPD with hypertrophy of nails, hyperkeratotic papules over body, lusterless and sparse hair and natal teeth since childhood. Microscopy nail clippings and scrapping were done to rule out fungal infection. No evidence of any associated malignancy was found after thorough workup. He was diagnosed as PC Type 2. This case is being reported because of its rarity.

**Keywords:** *pachyonychia congenita, genodermatosis, autosomal dominant, subungual hyperkeratosis, hyperkeratotic papules.*

## I. INTRODUCTION

Pachyonychia congenital (PC) is a rare genodermatosis having autosomal dominant pattern of inheritance with high penetration. PC mainly affects a number of ectodermal structures including nail bed, skin, teeth, oral mucosa and pilosebaceous unit. Nail involvement is commonest feature of PC which is usually present at birth or develops soon after birth. Muller and Wilson described the first case of PC<sup>1</sup>. On the basis of clinical features found in addition to the nail changes, PC has been classified into four types. Here, we report a rare case of PC type-2, known as Murray-Jackson-Lawler syndrome.

## II. CASE REPORT

A 2-year-old male child born of a nonconsanguineous marriage presented with thickened, yellowish brown discoloration of all the nails and multiple papules all over his body and ill formed lower incisor since birth [Figure 1]. Initially, at the time of birth, parents noticed natal tooth (ill formed lower incisor) and thickening of few nails of toes and fingers, which gradually increased over months and involved total twenty nails [Figure 2 a, b]. Later, at the age of 3 months parents also noticed small hyperkeratotic papules over both knees [Figure 3], which over a period of year

increased and involved bilateral upper limb, bilateral lower limb, trunk and buttocks. On examination, the nails showed thickened, lusterless nail plate of all the nails with upward growth of its distal portion. The nails also showed subungual hyperkeratosis and the nail plate was adhered to the underlying nail bed. There was increased curvature of the transverse axis of all nail plates giving a "pinched shape" to the free edge of the nail plate. Multiple hyperkeratotic follicular papules were present over bilateral upper limb, trunk, lower limbs and buttocks. He also had lusterless, sparse hair over scalp [Figure 4]. Systemic examination revealed no abnormality. The routine investigations were within the normal limits. Skin scraping for potassium hydroxide mount was negative for fungal elements. Patient's throat, and ophthalmological examination were normal. With all these findings the patient was diagnosed as PC type-2 and was started on topical retinoid and emollient for 1 month.

## III. DISCUSSION

Pachyonychia congenita is a rare group of disorder characterized by inherited ectodermal dysplasias transmitted in an autosomal dominant fashion. Some autosomal recessive cases also detected<sup>2</sup>. Sporadic case has been also detected with spontaneous mutation<sup>3</sup>. Pachyonychia congenita have four variants identified depending on the genetic mutation and clinical correlation<sup>3</sup>. (1) PC type-1 (Jadassohn Lewandowsky Syndrome) occurs because of mutations of the genes encoding keratin 6a and 16, characterized by subungual hyperkeratosis with dystrophic nail, focal palmoplantar keratoderma and follicular keratotic papules over body, (2) PC type-2 (Murray-Jackson-Lawler syndrome) occurs because of mutations of the genes encoding keratin 6b and 17, characterized by subungual hyperkeratosis with dystrophic nail, mild palmoplantar keratoderma, follicular keratotic papules, natal teeth and steatocystoma multiplex, (3) PC type-3 (Schafer-Branauer syndrome) characterized by subungual hyperkeratosis with dystrophic nail, focal palmoplantar keratoderma and follicular keratotic papules over body with angular cheilitis, corneal dyskeratosis, and cataracts, (4) PC type-4 characterized by subungual hyperkeratosis with dystrophic nail, focal palmoplantar keratoderma and follicular keratotic papules over body with laryngeal lesions, hoarseness of voice with mental retardation, hair abnormalities and alopecia. PC with late

**Author α ω:** MBBS, DDVL, Junior Resident, Dermatology, Venereology, Leprosy. e-mails: varshaverma62@yahoo.com, drpoojabonde@gmail.com

**Author σ:** MBBS, MD, Professor and Head, Department of Dermatology, Venereology, Leprosy, Mahatma Gandhi Institute of Medical Sciences. Sewagram, Maharashtra, 442102. e-mail: karmgims@gmail.com

**Author ρ:** MBBS, MD, Assistant Professor, Dermatology, Venereology & Leprosy. e-mail: ny.invincible@gmail.com

**Author ¥ § χ:** MBBS, Junior Resident, Dermatology, Venereology, Leprosy. e-mails: pooja.manwar24@gmail.com, kramteke@mgims.ac.in, patricksafa92@gmail.com

age of onset has been reported and termed as PC tarda<sup>4</sup>. The majority of mutations are missense mutations with a smaller number of deletions, insertions and splice site mutations in affected genes which leads to deleterious effects on protein structure as it interferes with the assembly of polypeptides forming the keratin structure of epidermal cell<sup>5</sup>.

The main characteristic symptom of this syndrome is hyperkeratosis of the nail bed. This type of subungual hyperkeratosis leads to the elevation and increased transverse curvature of the nail plate and also associated with discoloration, thickening and friability of nail plate<sup>6</sup>, which may sometimes fail to reach the distal fingertip. Generally all the 20 nails are affected but more severely thumbs, index fingers and toes nails are involved<sup>7</sup>.

The treatment in this syndrome is usually unsatisfactory. Topical application of salicylic acid, urea and 5-fluorouracil can be advice to the patient. The other treatment modalities include systemic therapy like

oral retinoids (acitretin, retinoic acid) and surgery<sup>8</sup>. A long term use of retinoids may results in to some degree of flattening of the nails and other complications such as periosteal hyperostosis, increased sensitivity and fragility of the underlying epidermis, and this limits their usefulness.<sup>9</sup> A genetic counselor also plays an important role as this gene has an autosomal dominant inheritance pattern and that PC can affect one half of his or her progeny, so counselor should inform the carrier. Nail findings persist for long, but other features may become less severe later in life.

Our patient belongs to PC type-2 as he had classical nail deformity along with hyperkeratotic papules over bilateral upper limb, bilateral lower limb, trunk and buttocks with natal teeth, and sparse lusterless thin hair over scalp. The patient did not show any of the other findings associated with other types of PC. This case is being reported because of its rarity.



*Figure 1:* Ill formed lower incisor since birth.





Figure 2 (a,b): Yellowish Brown discoloration of nails and thickening of all twenty nails.



Figure 3: Small hyperkeratotic papules over both knees.







Figure 4: Lusterless, sparse hair over scalp.

<sup>1</sup> Feinstein A, Friedman J, Schewach-Millet M. Pachyonychia congenita. *J Am Acad Dermatol* 1988; 19: 705-11.

<sup>2</sup> Haber R M, Rose T H. Autosomal recessive pachyonychia congenita. *Arch Dermatol* 1986; 122: 919-23.

<sup>3</sup> Sravanthi A, Srivalli P, Gopal K V, Rao T N. Pachyonychia congenita with late onset (PC tarda). *Indian Dermatol Online J.* 2016 Jul-Aug; 7(4): 278-80.

<sup>4</sup> Tiwary A K, Mishra D K. Jadassohn Lewandowsky syndrome: Type 1 pachyonychia congenita. *Our Dermatol Online.* 2017; 8(1): 56-59.

<sup>5</sup> Tiwary A K, Wilson N J, Schwartz M E, Smith F J. A novel KRT6A mutation in a case of pachyonychia congenital from India. *Indian J Dermatol Venereol Leprol* 2017; 83: 95-8.

<sup>6</sup> Agrawal S N, Kulkarni Y A, Jane S D, Deshmukh Y R. Pachyonychia congenita type-1 (Jadassohn-Lewandowsky syndrome). *Indian J Paediatr Dermatol* 2014; 15: 137-9.

<sup>7</sup> Leachman S A, Kaspar R L, Fleckman P, Florell S R, Smith F J, McLean W H, Lunny D P, Milstone L M, van Steensel M A, Munro C S, O'Toole E A, Celebi J T, Kansky A, Lane E B. Clinical and pathological features of pachyonychia congenita. *J Investig Dermatol Symp Proc.* 2005 Oct; 10(1): 3-17.

<sup>8</sup> Thomsen R J, Zuehlke R L, Beckman B I. Pachyonychia congenita: Surgical management of the nail changes. *J Dermatol Surg Oncol* 1982; 8: 24-8.

<sup>9</sup> Fernandez R J, Parikh D A. Pachyonychia Congenita. *Indian J Dermatol Venereol Leprol* 1989; 55: 334-5.





GLOBAL JOURNAL OF MEDICAL RESEARCH: F  
DISEASES

Volume 19 Issue 5 Version 1.0 Year 2019

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

## Association between Body Mass Index and Diabetic Complications among Type-2 Diabetic Patients in Semi-Urban Area, Bangladesh

By Md. Abdul Bashet, Most. Sabrina Moonajilin, Md. Abdul Majid, Md. Estiar Rahman,  
Md. Firoz Mahmud & Md. Sajib Rana

*Jahangirnagar University*

**Abstract- Aims:** The purpose of the study was to estimate the association between body mass index and diabetic complications of patients with type 2 diabetes mellitus in the semi-urban area (Savar), Bangladesh.

**Methods:** A cross-sectional study was conducted among 420 type-2 diabetic patients, picked up conveniently from Jahangirnagar University and nearest community, Savar, Dhaka. Body mass index (BMI) was calculated and categorized according to The WHO recommended Asian criteria. Diabetic complications were identified by clinical signs and symptoms using a questionnaire. Multiple logistic regression and Chi-square test were employed in data analysis.

**Keywords:** *type-2 diabetes; BMI; hypertension; nephropathy; neuropathy.*

**GJMR-F Classification:** NLMC Code: WK 810



*Strictly as per the compliance and regulations of:*



© 2019. Md. Abdul Bashet, Most. Sabrina Moonajilin, Md. Abdul Majid, Md. Estiar Rahman, Md. Firoz Mahmud & Md. Sajib Rana. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (<http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

# Association between Body Mass Index and Diabetic Complications among Type-2 Diabetic Patients in Semi-Urban Area, Bangladesh

Md. Abdul Bashet <sup>α</sup>, Most. Sabrina Moonajilin <sup>σ</sup>, Md. Abdul Majid <sup>ρ</sup>, Md. Estiar Rahman <sup>ω</sup>,  
Md. Firoz Mahmud <sup>¥</sup> & Md. Sajib Rana <sup>§</sup>

**Abstract- Aims:** The purpose of the study was to estimate the association between body mass index and diabetic complications of patients with type 2 diabetes mellitus in the semi-urban area (Savar), Bangladesh.

**Methods:** A cross-sectional study was conducted among 420 type-2 diabetic patients, picked up conveniently from Jahangirnagar University and nearest community, Savar, Dhaka. Body mass index (BMI) was calculated and categorized according to The WHO recommended Asian criteria. Diabetic complications were identified by clinical signs and symptoms using a questionnaire. Multiple logistic regression and Chi-square test were employed in data analysis.

**Results:** A total of 420 type-2 diabetic patients were investigated. Out of these, 248 were male, and 172 were female (mean±SD of age, 47.5±6.4 years). It was estimated that 23.8% had normal weight, 44.8% were overweight, and 31.4% were obese. The study found significant association between body mass index (BMI) and complications faced by the patients: BMI and hypertension ( $\chi^2=14.987$ ,  $df=2$ ,  $p=0.001$ ); BMI and neuropathy ( $\chi^2=14.697$ ,  $df=2$ ,  $p=0.001$ ); BMI and retinopathy ( $\chi^2=9.412$ ,  $df=2$ ,  $p=0.009$ ); BMI and nephropathy ( $\chi^2=25.503$ ,  $df=2$ ,  $p=0.000$ ). Multiple logistic regressions indicated that overweight and obese were significant predictors of diabetic complications ( $P<0.05$ ).

**Conclusion:** Globally, the prevalence of diabetes and overweight/obese have been increasing rapidly. People who are either overweight or obese accompanied by diabetes are at increased risk of developing complications. Therefore, weight control may reduce the risk of developing diabetes and its complications.

**Keywords:** type-2 diabetes; BMI; hypertension; nephropathy; neuropathy.

## I. INTRODUCTION

Diabetes has become a rapidly growing health burden worldwide.<sup>[1]</sup> American Diabetes Association (ADA) has defined Diabetes Mellitus(DM) as, “a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.”<sup>[2]</sup> DM is a disease known since ancient times, cited by both the

Greeks and Egyptians in as early as 4,500 BC.<sup>[3]</sup> An estimated 285 million people have type-2 diabetes globally, making up about 90 percent of all diabetes cases.<sup>[4]</sup> In the South Asian region, Bangladesh has the second largest number of diabetes patients with a prevalence rate of 11%.<sup>[5]</sup>

Almost all of the complications of diabetes are caused by having too much blood glucose.<sup>[6]</sup> Type 2 diabetes mellitus (T2DM) and its macro- and micro-vascular complications are a major threat to global public health.<sup>[7]</sup> The Centers for Disease Control and Prevention (CDC) reported that adults with diabetes are three times more likely than those without diabetes to have a history of coronary artery disease, three times more likely to have a stroke, and two times more likely to have another heart condition.<sup>[8]</sup> It is one of the major causes of premature illness and death in most countries worldwide. The World Health Organization (WHO) reported that diabetes was the seventh leading cause of death and contributed to an estimated 1.6 million deaths in 2016.<sup>[9]</sup> Complications Like premature atherosclerotic cardiovascular diseases, nephropathy leading to renal failure and peripheral neuropathy, cardiovascular symptoms. Hypertension and abnormalities of lipoprotein metabolism are often found in people with diabetes.<sup>[10]</sup>

Overweight and obesity are driving the global diabetes epidemic. They affect the majority of adults in most developed countries and are increasing rapidly in developing countries.<sup>[11]</sup> There are several studies indicating that weight loss and exercise may help in the treatment of diabetes. Weight loss and exercise have both been shown to decrease insulin resistance, a major physiological defect related to the development of diabetes, and to improve glycemic control. These interventions also ameliorate hypertension and lipid abnormalities and thus may contribute to a reduction in risk of coronary heart disease in individuals with T2DM.<sup>[12]</sup> Hypertension is a common problem in diabetic patients. Markedly increases the risk and accelerates the course of cardiac disease, peripheral vascular disease, stroke, and nephropathy. Hypertension is approximately twice as frequent in patients with diabetes compared with patients without the disease.<sup>[13]</sup>

Author <sup>α</sup> <sup>σ</sup> <sup>ρ</sup> <sup>ω</sup> <sup>¥</sup> <sup>§</sup>: Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka-1342, Bangladesh.  
e-mails: utsabsarker77@gmail.com, moonajilin@juniv.edu, chanchalahmed76@gmail.com, estiarju@gmail.com, firoz Mahmud21613@gmail.com, sajjibrana1992@gmail.com

The significance of the study is derived from the available statistics that reflect a high prevalence of DM in Bangladesh; more than 11 % and it will be increased 13% by 2030.<sup>[14]</sup> These huge number of people suffering from many kinds of diabetic complications which causes an increase in health care expenditures. So there is a need for research to reduce the diabetic morbidity. Moreover, to our knowledge, there is no study in a semi-urban area in Bangladesh that estimates of the association between a range of diabetes complications and Body Mass Index (BMI). Therefore, the current study aimed to estimate the association between diabetic complications and BMI at Jahangirnagar University and nearest Community, Savar, Bangladesh.

## II. MATERIALS AND METHODS

### a) Study design and population

It was a cross-sectional study conducted among diagnosed type-2 diabetic patients at Jahangirnagar University and the nearest community, Savar, Dhaka. The study was carried out in the year 2017 and 2018. A total of 420 patients with type-2 diabetes were selected conveniently. The sample size was determined by using the formula,  $n = z^2 pq/d^2$ .

### b) Data collection

Before collection, informed consent was taken from each patient. The purpose of the interview was clearly explained to the study subjects. A semi-structured questionnaire was used as the research instrument. Data were collected by face to face interview.

### c) Measures

Weight, height, and blood pressure were measured by using valid equipment. This study adopted the BMI definition of the World Health Organization (2000).<sup>[15]</sup> Body weight was measured to the nearest 100 gm. A professional weight machine was used for body weight measurement. The height was measured in centimeter by using a measuring tape. Blood pressure (systolic and diastolic) recordings were made after the subjects had rested in the sitting position for 10 minutes using a validated sphygmomanometer. Three separate readings were taken, and their mean was recorded.<sup>[16]</sup> Nephropathy, neuropathy, and retinopathy were diagnosed by clinical signs and symptoms using questionnaire.

### d) Data Analysis

Data were collected and analyzed using Statistical Package for Social Science (SPSS), version 20.0. Chi-square test was employed to test the association between variables. Linear multiple logistic regression was employed to identify predictors of diabetic complications. The statistically significant result means that the P-value is less or equal to 0.05.

## III. RESULTS

A total of 420 patients with type-2 diabetes mellitus (T2DM) were interviewed in the present study. The basic socio-demographic characteristics of the patients were shown in Table-1. The mean BMI of the patients was  $27.37 \pm 5.04$  Kg/m<sup>2</sup>. According to the BMI category, out of 420 patients, 23.8% had normal weight, 44.8% were overweight, and 31.4% were obese. (Table-1)

During the study period, blood pressure of the patients was measured. About 20% of the patients were found to be hypertensive. The patients were also asked about the complications they faced due to diabetes. The study found that 18.1% had diabetic neuropathy, 19.0% had diabetic nephropathy, and 21.9% of patients had diabetic retinopathy. (Table-2)

The study found significant association between body mass index (BMI) and complications faced by the patients: BMI and hypertension ( $\chi^2=14.987$ ,  $df=2$ ,  $p=0.001$ ); BMI and neuropathy ( $\chi^2=14.697$ ,  $df=2$ ,  $p=0.001$ ); BMI and retinopathy ( $\chi^2=9.412$ ,  $df=2$ ,  $p=0.009$ ); BMI and nephropathy ( $\chi^2=25.503$ ,  $df=2$ ,  $p=0.000$ ). (Table-3)

Logistic regression analysis further revealed that BMI was a significant predictor of complications arise among the patients with T2DM ( $p < .05$ ). Obese patients were 3.3 times more (OR=3.3, 95% CI=1.629-6.699;  $p=0.001$ ) and overweight patients were 1.5 times more (OR=1.5, 95% CI=0.737-3.069;  $p=0.001$ ) likely to develop hypertension than patients with normal weight. Similarly, obese patients were at more risk to develop neuropathy than patients with normal weight (OR=2.968, 95% CI=1.516-5.811;  $p=0.001$ ). Patients who were overweight were more prone to develop retinopathy than those who were normal (OR=2.804, 95% CI=1.417-5.549;  $p=0.011$ ). The results also show that patients who were overweight were more likely to develop nephropathy than patients with normal weight (OR=1.073, 95% CI=0.512-2.249;  $p=0.000$ ). Similarly, patients who were obese were about four times more likely to develop nephropathy than patients with normal weight (OR=3.667, 95% CI=1.815-7.409;  $p=0.000$ ). (Table-4)

## IV. DISCUSSION

Diabetes mellitus is a leading contributor to death and disability worldwide. The prevalence of diabetes and overweight/obese have increased rapidly worldwide.<sup>[18, 19]</sup> Similarly, the prevalence of diabetes and the percentage of people either overweight or obese have increased substantially in Bangladesh.<sup>[19]</sup> To our knowledge, there is no study in a semi-urban area in Bangladesh that estimates of the association between a range of diabetes complications and BMI. The present study provided the opportunity to estimate of the association between diabetic complications and BMI

among Jahangirnagar University community and nearest community in Savar, Bangladesh.

This study found that more or less twenty percent of the patients had a range of diabetic complications, including hypertension, neuropathy, retinopathy, and nephropathy. Diabetic patients with long term uncontrolled blood sugar may develop various serious complications. Among the most prevalent complications are kidney disease, blindness, and amputations reported in previous studies.<sup>[20, 21]</sup> Elevated blood pressure is observed in diabetic patients about 1.5 to 2 times more frequently than among non-diabetic patients.<sup>[22]</sup> The study estimated that almost half of the diabetic patients were overweight, whereas one-third of those were obese. Physical inactivity and patient's reluctances to follow dietary guideline may be the reasons for weight gain in Bangladesh.

Overweight and obesity are known to increase blood pressure, which is the leading cause of strokes. Excessive weight gain also increases the chances of developing other problems, including high cholesterol, high blood sugar, and heart disease.<sup>[23]</sup> Diabetic patients, either overweight or obese, are at increased risk of developing diabetic complications. Obesity accompanying with T2DM is known to be closely linked with insulin resistance and elevated sympathetic nervous activity.<sup>[24]</sup> It has been frequently reported in the literature that obesity, hypertension, and diabetes are high-risk factors for subsequent cardiovascular and renal complications. This study revealed that hypertension, neuropathy, retinopathy, and nephropathy were associated with BMI ( $p < 0.05$ ). More or less comparable results were reported in some previous studies.<sup>[22, 24, 25]</sup> Weight control is an important step for the management of diabetic complications. Physical activity helps to maintain a healthy weight. Regular exercise may bring about many possible health benefits, and contribute to weight loss, prevent weight regain, improve insulin sensitivity, glycaemic control.<sup>[26]</sup>

## V. CONCLUSION

Globally the prevalence of diabetes and overweight/obese have been increasing rapidly. People who are either overweight or obese accompanied by diabetes are at increased risk of developing complications. Therefore, weight control may reduce the risk of developing diabetes and its complications.

## VI. DECLARATIONS

*Funding*  
Self.

*Ethical issues*

This study was conducted maintaining ethical standards to the highest possible extent. Before the assessment, informed consent was taken from all the patients, participated in this study. This study was

approved by the Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka. The study was also followed by "recommendations guiding physicians in biomedical research involving human subjects," adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964.

*Conflict of interest*

No conflict of interest.

## ACKNOWLEDGMENT

We acknowledge the contribution of our team members. We also thank to the patients who voluntarily participate in this study.

## LIMITATIONS

The study was not free of limitation. The population was selected conveniently, so there might be a chance of bias. Limited sample size due to self-funding may restrict for generalization. The limited resources such as reports, statistical data, books, and journals were also a limitation.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. Chiasson J-L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. *The Lancet* 2002; 359(9323): 2072-7.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010; 33(Supplement 1): S62-9.
3. Width M, Reinhard T. The clinical dietitian's essential pocket guide. Lippincott Williams & Wilkins Philadelphia; 2009.
4. Ahlam M S, Ganai B, Zargar M, Seema A. In vivo study of anti-diabetic activity of *Eremurus himalaicus*. 2013.
5. Federation I D. IDF diabetes atlas. Bruss Int Diabetes Fed 2013.
6. American Diabetes Association. Total prevalence of diabetes & pre-diabetes. Am Diabetes Assoc Httpdiabetes Orgdiabetes-Stat Jsp Accessed April 18 2008 2008.
7. World Health Organization. Diabetes action now: an initiative of the World Health Organization and the International Diabetes Federation. 2004.
8. Centers for Disease Control and Prevention (CDC). Self-reported heart disease and stroke among adults with and without diabetes--United States, 1999-2001. *MMWR Morb Mortal Wkly Rep* 2003; 52(44): 1065.
9. Diabetes [Internet]. [cited 2019 Mar 17]; Available from: <https://www.who.int/news-room/fact-sheets/detail/diabetes>
10. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories



of glucose intolerance. *Diabetes* 1979; 28(12): 1039–57.

11. Kelly T, Yang W, Chen C-S, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. *Int J Obes* 2008; 32(9): 1431.
12. Maggio C A, Pi-Sunyer F X. The prevention and treatment of obesity: application to type 2 diabetes. *Diabetes Care* 1997; 20(11): 1744–66.
13. Sowers J R, Epstein M, Frohlich E D. Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension* 2001; 37(4): 1053–9.
14. Federation I D. *IDF diabetes atlas*. Bruss Int Diabetes Fed 2013.
15. World Health Organization. *Obesity: preventing and managing the global epidemic*. World Health Organization; 2000.
16. Pickering T G, Hall J E, Appel L J, Falkner B E, Graves J, Hill M N, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. *Circulation* 2005; 111(5): 697–716.
17. Chen L, Magliano D J, Zimmet P Z. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. *Nat Rev Endocrinol* [Internet] 2012 [cited 2019 Mar 17]; 8(4): 228–36. Available from: <https://www.nature.com/articles/nrendo.2011.183>
18. Reilly J J, El-Hamdouchi A, Diouf A, Monyeki A, Somda SA. Determining the worldwide prevalence of obesity. *The Lancet* [Internet] 2018 [cited 2019 Mar 17]; 391(10132): 1773–4. Available from: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(18\)30794-3/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30794-3/abstract)
19. Akter S, Rahman M M, Abe S K, Sultana P. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. *Bull World Health Organ* 2014; 92: 204–213A.
20. Forbes J M, Cooper M E. Mechanisms of Diabetic Complications. *Physiol Rev* [Internet] 2013 [cited 2019 Mar 17]; 93(1): 137–88. Available from: <https://www.physiology.org/doi/full/10.1152/physrev.00045.2011>
21. Singh R, Kaur N, Kishore L, Kumar Gupta G. Management of diabetic complications: A chemical constituents based approach. *J Ethnopharmacol* [Internet] 2013 [cited 2019 Mar 17]; 150(1): 51–70. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0378874113006053>
22. Arauz-Pacheco C, Raskin P. Hypertension in diabetes mellitus. *Endocrinol Metab Clin* 1996; 25(2): 401–423.
23. Health Risks of Being Overweight | NIDDK [Internet]. *Natl. Inst. Diabetes Dig. Kidney Dis.* [cited 2019 Mar 17]; Available from: <https://www.niddk.nih.gov/health-information/weight-management/health-risks-overweight>
24. Masuo K, Rakugi H, Ogihara T, Esler M D, Lambert GW. Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. *Curr Diabetes Rev* 2010; 6(2): 58–67.
25. Idogun E S, Unuigbo E I, Famodu A A, Akinola O T. Body mass index in type 2 diabetes mellitus complications: hypertensive diabetics and diabetic nephropathy. *Niger Postgrad Med J* 2006; 13(1): 17–20.
26. Bukht M S, Ahmed K R, Hossain S, Masud P, Sultana S, Khanam R. Association between physical activity and diabetic complications among Bangladeshi type 2 diabetic patients. *Diabetes Metab Syndr Clin Res Rev* 2019; 13(1): 806–809.

*Table 1:* Socio-demographic characteristics of the patients with T2DM (n=420)

Variables	Frequency	Percentage (%)	Mean(±SD)
<b>Socio-demographics</b>			
<b>Gender</b>			
Male	248	59.0	
Female	172	41.0	
<b>Age (years)</b>			
30-40	60	14.3	47.2(±6.4)
40-50	204	48.6	
>50	156	37.1	
<b>Education</b>			
Low educated (1-9)	224	53.3	
High educated (>9)	196	46.7	
<b>Employment status</b>			
Unemployed	144	34.3	
Employed	276	65.7	
<b>Marital status</b>			
Unmarried	12	2.9	

Married	408	97.1	
<b>Monthly income (BDT)</b>			
5,000-15,000	116	27.6	25,305 (±11,507)
15,000-30,000	208	49.5	
>30,000	96	22.9	

Table 2: Complications reported by the patients with T2DM (n=420)

Complications	Frequency	Percentage (%)
<b>Hypertension</b>		
Yes	85	20.2
No	335	79.8
<b>Neuropathy</b>		
Yes	90	21.4
No	330	78.6
<b>Retinopathy</b>		
Yes	92	21.9
No	328	78.1
<b>Nephropathy</b>		
Yes	80	19.0
No	340	81.0

Table 3: Distribution of various complications of the patients with T2DM according to BMI category (n=420)

Variables	Total (420); n (%)	Complications; n (%)	X <sup>2</sup> test value	df	p-value
<b>BMI</b>		<b>Hypertension</b>			
Normal	100(23.8)	12 (12.0%)	14.987	2	.001
Overweight	188(44.8)	32(17.0)			
Obese	132(31.4)	41(31.1%)			
<b>BMI</b>		<b>Neuropathy</b>			
Normal	100(23.8)	14(14.0%)	14.697	2	.001
Overweight	188(44.8)	33(17.6%)			
Obese	132(31.4)	43(32.6%)			
<b>BMI</b>		<b>Retinopathy</b>			
Normal	100(23.8)	12(12.0%)	9.412	2	.009
Overweight	188(44.8)	52(27.7%)			
Obese	132(31.4)	28(21.2%)			
<b>BMI</b>		<b>Nephropathy</b>			
Normal	100(23.8)	12(12.0%)	25.503	2	.000
Overweight	188(44.8)	24(12.8%)			
Obese	132(31.4)	44(33.3%)			

Table 4: Association of BMI category with various complications of the patients with T2DM as explored by binary logistic regression (n =420)

Variables	Unadjusted Model		
	Odds Ratio (OR)	95% Confidence Interval (CI)	p-value
<b>BMI</b>			
<b>Hypertension</b>			
Normal	Ref		.001
Overweight	1.504	(0.737-3.069)	
Obese	3.304	(1.629-6.699)	
<b>BMI</b>			
<b>Neuropathy</b>			
Normal	Ref		.001
Overweight	1.308	(0.664-2.577)	
Obese	2.968	(1.516-5.811)	
<b>BMI</b>			
<b>Retinopathy</b>			
Normal	Ref		.011
Overweight	2.804	(1.417-5.549)	
Obese	1.974	(0.948-4.111)	
<b>BMI</b>			
<b>Nephropathy</b>			
Normal	Ref		.000
Overweight	1.073	(0.512-2.249)	
Obese	3.667	(1.815-7.409)	





This page is intentionally left blank



# Functional Dietary Supplementation of Okara (Soybeans Residue) on Streptozotocin Induced Diabetes Mellitus in Male Wistar Rats

By Nwozo Sarah O, Ikpeme Grace E & Nwawuba Stanley U

*University of Ibadan*

**Abstract-** A poor dietary habit has been demonstrated to be one of the key players in the development of diabetes mellitus, and a diet rich in dietary fiber has been highlighted to be a potent candidate for the management of diabetes mellitus. Therefore, this study is aimed to validate the role of dietary supplementation of okara (soybeans residue) in streptozotocin induced diabetic male Wistar rats. The total of 28 rats between the weight of 100 to 105g, was grouped into four n=7, and this study spanned for a period of 43days. All experimentations were conducted using standard method, and our findings show that the cumulative feed intake of 15% okara diet supplementation was significantly higher  $p < 0.05$  particularly from day 29 to day 43 relative to the negative control. After treatment for a period of 43 days, 6mg/kg glibenclamide treated group  $226.33 \pm 6.38$  and 15% okara supplemented diet fed group  $219.83 \pm 5.67$  showed a significant increase  $p < 0.05$  in body weight relative to the Negative control  $161.17 \pm 3.60$ . 15% okara diet supplementation significantly lowered  $p < 0.05$  blood sugar levels after treatment relative to after induction similar to 6mg/kg glibenclamide treated group.

**Keywords:** diabetes mellitus, liver function, okara diet, lipid profile, and glycated hemoglobin.

**GJMR-F Classification:** NLMC Code: WK 810



*Strictly as per the compliance and regulations of:*



# Functional Dietary Supplementation of Okara (Soybeans Residue) on Streptozotocin Induced Diabetes Mellitus in Male Wistar Rats

Nwozo Sarah O <sup>α</sup>, Ikpeme Grace E <sup>σ</sup> & Nwawuba Stanley U <sup>ρ</sup>

**Abstract-** A poor dietary habit has been demonstrated to be one of the key players in the development of diabetes mellitus, and a diet rich in dietary fiber has been highlighted to be a potent candidate for the management of diabetes mellitus. Therefore, this study is aimed to validate the role of dietary supplementation of okara (soybeans residue) in streptozotocin induced diabetic male Wistar rats. The total of 28 rats between the weight of 100 to 105g, was grouped into four n=7, and this study spanned for a period of 43days. All experimentations were conducted using standard method, and our findings show that the cumulative feed intake of 15% okara diet supplementation was significantly higher  $p < 0.05$  particularly from day 29 to day 43 relative to the negative control. After treatment for a period of 43days, 6mg/kg glibenclamide treated group  $226.33 \pm 6.38$  and 15% okara supplemented diet fed group  $219.83 \pm 5.67$  showed a significant increase  $p < 0.05$  in body weight relative to the Negative control  $161.17 \pm 3.60$ . 15% okara diet supplementation significantly lowered  $p < 0.05$  blood sugar levels after treatment relative to after induction similar to 6mg/kg glibenclamide treated group. Glycated hemoglobin, glucose-6-phosphate dehydrogenase, lipid profile (CHOL, TRIG, LDL and HDL), liver function enzymes (AST, ALT, ALP and GGT), kidney function biomarkers (Creatinine, Urea, Sodium and potassium) and antioxidant enzymes (CAT, SOD, GSH, GST and GPX) were all significantly restored within the normal range. Histological observations of the pancreatic, liver, and kidney tissue showed no visible lesion for 15% Okara supplemented diet feeding. Conclusively, we recommend food supplementation with Okara.

**Keywords:** diabetes mellitus, liver function, okara diet, lipid profile, and glycated hemoglobin.

## 1. INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder whereby either the pancreas does not produce enough insulin (a hormone that regulates hyperglycemia), or situation where the body cannot effectively use the insulin it produced [1]. Correspondingly, DM has not only assumed a pandemic proportions worldwide but has also proven to affect the developing countries of the world much more than their developed counterparts [2]. Of course, DM has been demonstrated to be a prime global health concern with

a projected rise in prevalence from 171 million in 2010 to 366 million in 2030 [1]. Disturbingly, both the number of cases and the prevalence of DM has steadily been showed to be on the rise over the past few decades, and it is regarded to be a silent killer disease, affecting millions of peoples in the world [3, 4]. Considering Africa, studies has revealed that, the number of people with diabetes will increase from 14.2 million in 2015 to 34.2 million in 2040 with majority of the cases predominated in some of the region's most populous countries like: South Africa, the Democratic Republic of Congo, Nigeria, and Ethiopia [2, 3].

Regardless of the numerous conventional medications that have been in use for the management of DM, its inaccessibility has been a limitation as a result of the relatively high cost and sometimes unavailability [5]. In this light, of course, a switch to a readily available and cheaper alternative has become necessary in the form of phyto/herbal medicine [5]. Herbal medicine similarly referred as phytomedicine; alludes to the use of plants seeds, flowers, roots for medicinal purpose and even today, plant materials continue to play an important role in primary health care as a therapeutic remedy in many developing countries [5]. As reported, the World Health Organization (WHO) recently recommended the use of medicinal plants for the management of DM and further encouraged the expansion of the frontiers for scientific evaluation on the hypoglycemic properties of diverse plant species [5,6].

Soybean-based foods have shown to be beneficial on human health and currently the consumption of soybean products elevated due to functional food improving knowledge [7,8]. Generally, it has been demonstrated that a diet high in fiber is useful in the management of the plasma glucose concentration in individuals with diabetes [9]. The beneficial metabolic effects of dietary fiber are long lasting and clinically relevant both in types 1 and type 2 diabetic patients [10]. Also, Fiber has been studied in the treatment of diabetes for many years because increased fiber content has been shown to decrease the glycemic index of foods. The theory, then, is that the decreased glycemic index would lead to smaller increases in blood glucose, and thus reduced blood glucose and HbA1c levels [11].

Author <sup>α</sup> <sup>σ</sup> <sup>ρ</sup>: Nutritional and Industrial Research Laboratories, Department of Biochemistry, Faculty of Basic Medical Science, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria, 200005. e-mails: sonwozo@yahoo.com, onyenibe.nwozo@mail.ui.edu.ng

Okara is the insoluble residue from soybean after milk production and is mainly rich in dietary fiber 50–60% and protein 30% [12]. Its dietary fiber has 12% hemicellulose, 5.6% cellulose, 12% lignin, and 0.16% phytic acid [13]. Because of its high fiber content, okara is used as a supplement in human diets, particularly western diets, which are deficient of the essential fiber [12]. Although there have been several reports on the nutraceutical power of okara [7, 14, 15], still, the use is not yet a common practice, as most people still dispose of it in the form of chaff after extraction. In this light, continual evaluation and research are required to validate and update the existing report on the health benefit of okara. Therefore, the aim of this study was to investigate the antidiabetic ability of okara (soybean residue) on streptozotocin induced diabetic male Wistar rats.

## II. MATERIAL AND METHODS

### a) Seed collection and preparation

Soybean Seeds were purchased from Bodija market, Ibadan, Oyo State. Thereafter, it was identified by a botanist in the Botany Department of the University of Ibadan. The seeds were sorted manually to remove defective seeds and other extraneous materials and then washed. The washed soybean seeds were blanched in hot water for 25 minutes at 100°C and then dehulled. The dehulled cotyledons were washed with hot (100°C) water twice and wet milled using 5 litres of water to 1 kg of the soybean seeds. The slurry obtained was mixed and filtered through a muslin cloth to remove the milk and recover the residue called okara. The fresh okara was dried using a hot-air dryer at a temperature of 70°C, milled and sieved through 0.25 mm pore sized sieve. Okara flour was then packaged hermetically and stored for analyses and diet formulation.

### b) Analysis of feed

We carried out a proximate content analysis for protein, fat, ash, fiber and moisture according to a standard procedure as described by [16], and mineral (calcium and phosphorus) content analyses were carried out using Atomic Absorption Spectrophotometry (AAS).

Table 1: Feed Composition

Parameters	Normal Diet (%)	Okara Diet (%)
Protein	21	24.5
Ash	1.3	4.2
Moisture	4.6	7.4
Fat	3.5	3.2
Fibre	6.0	40.8
Calcium	0.8	0.9
Phosphorus	0.8	0.72
Okara	-	15
Dry Matter	-	91.38%

### c) Chemical

All the chemicals used in this study were of analytical grade unless stated otherwise. Streptozotocin (Santa Cruz, U.S.A), Potassium chloride (BDH Chemical Ltd, England), dipotassium hydrogen phosphate  $K_2HPO_4$  (Hopkins and Williams Ltd. England) and anhydrous potassium dihydrogen phosphate  $KH_2PO_4$  (BDH Chemical Ltd. England)

### d) Animals used

For this study, a total of 28 male Wistar rats between the weights of 100-105g were procured from the central animal house, College of Medicine, University of Ibadan, Nigeria. The male Wistar rats were kept in well-kept and ventilated cages, and their beddings changed every three days, and were allowed free access to clean drinking water. The rats were allowed to acclimatize for two weeks before commencement of experimentation, and all the processes involved in handling and experiment were carried out according to standard protocols approved by the animal ethics committee of the department.

### e) Induction of Hyperglycemia with Streptozotocin

Hyperglycaemia was induced with a single dose of intraperitoneal injection of streptozotocin. 50 mg/kg of streptozotocin was dissolved in (0.1 M, pH 4.5) citrate buffer and after 72 hours; ACCU-CHEK Glucometer was used to measure blood sugar level from blood samples collected from a caudal vein of the rats. Blood sugar levels between the values of  $(326.50 \pm 3.56$  to  $327.00 \pm 4.85$  mg/dl) were taken to be diabetic and the values in the range of  $(88.67 \pm 2.16$  to  $97.67 \pm 1.51$  mg/dl) were taken to be normal in this study.

### f) Measurements of food intake and body weight

Daily food intake was derived by (final feed weight – initial feed weight) on a daily basis throughout the experimentation, and body weight was taken weekly with an electronic balance.

### g) Experimental design

Each group contained seven animals.

Group 1: Normal Control fed with a normal diet.

Group 2: Negative control received 50mg/kg STZ, fed a normal diet and remained untreated.

Group 3: Positive control received 50mg/kg STZ, fed normal diet, and treated with glibenclamide 6mg/kg as used by [17].

Group 4: Received 50mg/kg STZ, fed 15% okara supplemented diet as used by [7].

### h) Biochemical analysis

ACCU-CHEK glucometer was used to measure blood sugar level, glucose-6-phosphate dehydrogenase (G6PD) was measured by spectrophotometric method using Randoxkits, Randox kit method of enzymatic hydrolysis described by [18] was used for determination

of triglyceride, total cholesterol, and high-density lipoprotein-cholesterol. Glycated hemoglobin (HBA1c) was measured at the end of the study using a high-performance liquid chromatography (HPLC) technique. Serum level of alanine and aspartate aminotransferases (ALT and AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), creatinine, urea, sodium, and potassium levels were measured by spectrophotometric method using Randox kits. Superoxide dismutase (SOD) activity was measured using the method of [19] as previously described by [1], catalase (CAT) activity was measured using the method of [20] as previously described by [1], reduced glutathione (GSH) concentration was estimated using the method of [21] as previously described by [1], Glutathione-S-transferase activity was determined following the method of [22] as previously described by [1], and Glutathione peroxidase (GPX) activity was estimated following the method of [23].

*i) Histopathological Studies*

Small pieces of the pancreatic, liver, and kidney tissues were fixed in 10% formalin solution, followed by embedding in melted paraffin wax. Histopathological assessment and photomicrography of the prepared slides were done by using an Olympus light Microscope with attached Kodak digital camera as previously described by [1].

*j) Statistical analysis*

As previously reported in [1], data were analyzed using ANOVA (analysis of variance) and mean

separation was done using Duncan multiple range test and HSD Turkey. Paired T-test was used to establish a difference in timely events. P values less than 0.05 ( $p < 0.05$ ) were considered significant. Data were expressed as means  $\pm$  standard deviation and pictorially presented in the form of charts. All statistical analysis was done using IBM SPSS Version 22 and Microsoft Excel.

III. RESULTS

*a) Feed intake*

Table 2 shows the cumulative feed intake of male Wistar rats. Following two weeks of acclimatization, the weight of the feed consumed by each group was recorded on a daily basis, summed up and reported weekly as day 1, day 8, day 15, day 22, day 29, day 36 and day 43 respectively. On day 1, there was no significant difference  $p > 0.05$  in the amount of feed consumed between all the groups. However, the experimental groups (B, C, and D) intraperitoneally injected with 50mg/kg streptozotocin showed a significant increase  $p < 0.05$  in cumulative feed intake relative to the normal control at day 8, day 15 and day 22 respectively. Interestingly, the cumulative feed intake from day 29 up till day 43 for 15% okara supplemented diet fed group was significantly different  $p < 0.05$  the negative control and showed no significant difference  $p > 0.05$  as compared to the normal control.

Table 2: Cumulative feed intake of male Wistar rats

G	Day 1	Day 8	Day 15	Day 22	Day 29	Day 36	Day 43
A	24.8 $\pm$ 1.17 <sup>a</sup>	33.7 $\pm$ 1.03 <sup>a</sup>	50.3 $\pm$ 1.63 <sup>a</sup>	62.7 $\pm$ 5.61 <sup>a</sup>	96.3 $\pm$ 5.28 <sup>a</sup>	132.3 $\pm$ 1.51 <sup>c</sup>	174.8 $\pm$ 1.72 <sup>c</sup>
B	25.0 $\pm$ 1.41 <sup>a</sup>	42.2 $\pm$ 0.75 <sup>b</sup>	71.3 $\pm$ 1.63 <sup>b</sup>	93.3 $\pm$ 2.07 <sup>b</sup>	105.7 $\pm$ 0.82 <sup>b</sup>	119.2 $\pm$ 2.23 <sup>a</sup>	156.2 $\pm$ 1.17 <sup>a</sup>
C	24.5 $\pm$ 1.64 <sup>a</sup>	42.8 $\pm$ 1.47 <sup>bc</sup>	72.8 $\pm$ 2.04 <sup>b</sup>	92.8 $\pm$ 2.56 <sup>b</sup>	117.5 $\pm$ 1.52 <sup>c</sup>	128.7 $\pm$ 2.42 <sup>b</sup>	165.0 $\pm$ 2.10 <sup>b</sup>
D	24.7 $\pm$ 1.21 <sup>a</sup>	44.2 $\pm$ 1.47 <sup>c</sup>	73.5 $\pm$ 1.87 <sup>b</sup>	93.3 $\pm$ 1.63 <sup>b</sup>	125.7 $\pm$ 1.63 <sup>d</sup>	131.5 $\pm$ 1.52 <sup>bc</sup>	173.3 $\pm$ 3.27 <sup>c</sup>

Mean value with the same alphabet as superscript within each column variable are non-significant ( $p > 0.05$ ). The abbreviations represent G: Groups, A: Normal Control, B: Negative Control, C: Positive Control, D: 15% Okara Diet supplementation.

*b) Body weight*

Figure 1 demonstrates the effect of 15% okara diet on body weight (g). Following two (2) weeks of acclimatization, the rats body weights were taken and reported as initial body weight, and there was no observed significant difference  $p > 0.05$  between all groups. However, after the experimental groups received 50mg/kg streptozotocin intraperitoneal injection, the body weights were recorded after 7 days, and the result revealed that there was a significant reduction  $p < 0.05$  in body weight of all experimental groups; negative control 138.17 $\pm$ 2.86, positive control 138.17 $\pm$ 1.33 and 15% okara supplemented diet fed group 140.50 $\pm$ 2.81 relative to the normal control 150.67 $\pm$ 2.73. The final body weights of the rats were recorded after treatment for a period of 43 days, 6mg/kg

glibenclamide treated group 226.33 $\pm$ 6.38 and 15% okara supplemented diet fed group 219.83 $\pm$ 5.67 showed a significant increase  $p < 0.05$  in body weight relative to the Negative control 161.17 $\pm$ 3.60. Similarly, the normal control also showed a significant weight increase  $p < 0.05$  compared to the negative control.




Figure 1: Effect of 15% Okara supplemented diet on body weight of male Wistar rats

\* Significant (P<0.05) vs. Initial body weight

\*\* Significant (P<0.05) vs. Body weight after streptozotocin injection

c) Blood sugar levels

Figure 2 shows the effect of 15% okara supplementation diet on blood sugar levels. Baseline blood sugar levels were recorded after two (2) weeks of acclimatization; Blood sugar levels after induction were recorded after 72 hours of intraperitoneal injection of 50mg/kg streptozotocin, and after treatment at end of 43days, blood sugar levels were also recorded. Normal control showed no significant variation p>0.05 in blood

sugar levels, after treatment 97.67±1.51 relative to after induction 92.67±4.21, after induction relative to baseline 89.17±1.72. The experimental groups showed a significant elevation p<0.05 in blood sugar level after induction relative to the baseline. However, 15% okara diet supplementation and 6mg/kg glibenclamide treated group significantly lowered p<0.05 blood sugar levels after treatment relative to after induction.




Figure 2: Effect of 15% Okara supplemented diet on blood sugar levels of male Wistar rats

\* Significant (P<0.05) vs. Initial Baseline

\*\* Significant (P<0.05) vs. Body after induction



d) *Glucose-6-phosphate dehydrogenase and glycated hemoglobin*

Table 3 showed that G6PD ranged from (Normal Control)  $91.33 \pm 4.32$  to  $46.00 \pm 2.83$  (Negative Control-Untreated diabetics) and HBA1c ranged from (Normal Control)  $4.62 \pm 0.28$  to  $11.28 \pm 0.54$  (Negative

Control-Untreated diabetics). In each parameter assay, 15% okara supplemented diet, 6mg/kg glibenclamide (positive control) treated group, and the normal control showed a significant increase  $p < 0.05$  and a significant decrease  $p < 0.05$  relative to the negative control.

Table 3: Effect of 15% okara supplemented diet on HBA1c and G6PD

GROUPS	G6PD	HBA1c %
Normal Control	$91.33 \pm 4.32^d$	$4.62 \pm 0.28^a$
Negative Control	$46.00 \pm 2.83^a$	$11.28 \pm 0.54^d$
Positive Control	$74.50 \pm 5.21^c$	$6.37 \pm 0.36^b$
15% Okara Diet	$58.17 \pm 2.56^b$	$7.57 \pm 0.52^c$

Mean value with the same alphabet as superscript within each column variable are non-significant ( $p > 0.05$ ). The abbreviations represent G6PD: glucose-6-phosphate dehydrogenase, HBA1c: Glycated hemoglobin.

e) *Lipid Profile*

Table 4 shows the effect of 15% okara supplemented diet on lipid profile. At the end of 43 days of treatment, blood samples were collected from the rats, and plasma levels of lipid profile parameters (CHOL, TRIG, LDL, and HDL) were determined. Negative control (untreated group) showed a significant

elevation  $p < 0.05$  in the levels of CHOL, TRIG, LDL, and a significant decrease in the levels of HDL relative to the Normal control. However, the treated groups (15% okara diet and positive control) significantly lowered  $p < 0.05$  CHOL, TRIG, LDL, and elevated levels of HDL relative to the untreated group (Negative control).

Table 4: Effect of 15% okara supplemented diet on lipid profile

Groups	CHOL	TRIG	LDL	HDL
Normal Control	$51.00 \pm 1.55^a$	$34.83 \pm 2.23^a$	$17.00 \pm 1.67^a$	$40.00 \pm 3.74^c$
Negative Control	$70.17 \pm 1.17^c$	$51.67 \pm 1.86^d$	$28.67 \pm 1.63^c$	$21.83 \pm 1.17^a$
Positive Control	$57.50 \pm 3.39^b$	$41.00 \pm 1.41^b$	$20.50 \pm 1.87^b$	$30.17 \pm 1.60^b$
15% Okara Diet	$56.17 \pm 1.17^b$	$44.67 \pm 1.75^c$	$22.17 \pm 2.48^b$	$30.17 \pm 2.14^b$

Mean value with the same alphabet as superscript within each column variable are non-significant ( $p > 0.05$ ). The abbreviations represent CHOL: cholesterol, TRIG: triglyceride, LDL: low-density lipoprotein, HDL: high-density lipoprotein.

f) *Liver function*

At the end of the experimentation, the rats blood samples were collected, and serum levels of liver function biomarkers ALT, AST, ALP, and GGT respectively were determined as demonstrated in table 5. Negative control which had remained untreated after

50mg/kg intraperitoneal streptozotocin injection showed a significant elevation  $p < 0.05$  in all liver biomarkers assayed for relative to the normal control. However, 15% okara supplemented diet and 6mg/kg glibenclamide significantly lowered  $p < 0.05$  levels of liver biomarkers vis-à-vis negative control.

Table 5: Effect of 15% okara supplemented diet on liver function

Groups	ALT(U/l)	AST(U/l)	ALP(U/l)	GGT(U/l)
Normal Control	$32.33 \pm 2.94^a$	$39.50 \pm 2.34^a$	$125.67 \pm 2.94^a$	$5.67 \pm 1.21^a$
Negative Control	$44.67 \pm 2.01^b$	$53.67 \pm 2.34^b$	$164.17 \pm 2.86^b$	$15.67 \pm 1.63^b$
Positive Control	$58.83 \pm 2.23^c$	$63.67 \pm 2.94^c$	$143.25 \pm 2.51^c$	$9.00 \pm 0.89^c$
15% Okara diet	$44.00 \pm 2.53^b$	$51.67 \pm 1.86^b$	$144.33 \pm 4.80^b$	$8.17 \pm 0.98^b$

Mean value with the same alphabet as superscript within each column variable are non-significant ( $p > 0.05$ ). The abbreviations represent ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, ALP: Alkaline Phosphatase, GGT: Gamma-Glutamyltransferase.

g) *Kidney Function*

Table 6 shows the effect of 15% okara supplemented diet in male Wistar rats. Serum levels of kidney function markers creatinine, urea, potassium, and sodium respectively were determined at the end of the experimentation. The experimental groups received 50mg/kg streptozotocin intraperitoneal injection. However, the negative control which remained untreated showed a significant increase  $p < 0.05$  in the levels of

kidney function markers relative to the normal control and treatment with 15% okara supplemented diet feeding significantly  $p < 0.05$  lowered the levels in comparison with the negative control and of course similar with the positive control.

Table 6: Effect of 15% okara supplemented diet on kidney function

Groups	Creatinine	Urea	Potassium	Sodium
Normal Control	51.67±1.03 <sup>a</sup>	15.17±1.17 <sup>a</sup>	6.50±0.55 <sup>a</sup>	147.50±2.17 <sup>a</sup>
Negative Control	70.00±1.41 <sup>c</sup>	26.67±1.37 <sup>b</sup>	10.67±1.21 <sup>c</sup>	164.17±3.00 <sup>c</sup>
Positive Control	53.00±0.89 <sup>a</sup>	18.00±1.72 <sup>a</sup>	8.83±1.72 <sup>b</sup>	152.67±1.63 <sup>b</sup>
15% Okara diet	55.50±1.05 <sup>b</sup>	17.00±2.83 <sup>a</sup>	8.00±0.89 <sup>ab</sup>	153.00±2.10 <sup>b</sup>

Mean value with the same alphabet as superscript within each column variable are non-significant ( $p > 0.05$ ).

h) Antioxidant Enzyme

Table 7 demonstrates the effect of 15% okara diet on selected organs of male Wistar rats. Following 43 days of experimentation, liver, kidney, and pancreas were harvested, homogenized, cold centrifuged, supernatants collected and used for determination of selected antioxidant enzyme levels. Interestingly, levels of catalase (CAT), superoxide dismutase (SOD), reduced glutathione (GSH), glutathione-s-transferase

(GST), and glutathione peroxidase (GPX) for liver, kidney, and pancreas respectively were significantly decreased  $p < 0.05$  in the negative control group relative to the normal control. However, 15% okara diet supplemented fed group, and 6mg/kg glibenclamide treated group that was exposed to same levels of streptozotocin as the negative control showed a significant increase  $p < 0.05$  in the levels of selected antioxidant enzymes vis-à-vis negative control.

Table 7: Effect of 15% okara supplemented diet on Liver, Kidney and Pancreatic Antioxidant levels

GROUPS	CATALASE	SOD	LIVER		
			GSH	GST	GPX
Normal Control	39.60±1.14 <sup>c</sup>	43.60±2.30 <sup>d</sup>	83.20±1.92 <sup>d</sup>	38.40±1.14 <sup>d</sup>	33.00±1.58 <sup>c</sup>
Negative Control	15.00±1.58 <sup>a</sup>	22.00±1.58 <sup>a</sup>	39.00±1.58 <sup>a</sup>	11.20±1.92 <sup>a</sup>	12.80±1.48 <sup>a</sup>
Positive Control	26.20±1.92 <sup>b</sup>	35.60±1.14 <sup>c</sup>	62.00±3.58 <sup>c</sup>	26.40±2.30 <sup>c</sup>	25.00±1.87 <sup>b</sup>
15% Okara Diet	24.20±2.77 <sup>b</sup>	30.10±1.14 <sup>b</sup>	56.40±3.36 <sup>b</sup>	21.40±2.30 <sup>b</sup>	22.20±1.92 <sup>b</sup>
			KIDNEY		
Normal Control	33.60±1.14 <sup>d</sup>	35.40±2.30 <sup>c</sup>	64.80±3.11 <sup>d</sup>	33.40±2.70 <sup>c</sup>	32.20±1.92 <sup>c</sup>
Negative Control	10.20±1.92 <sup>a</sup>	16.80±2.28 <sup>a</sup>	33.00±3.16 <sup>a</sup>	18.20±4.76 <sup>a</sup>	11.00±1.87 <sup>a</sup>
Positive Control	25.20±1.30 <sup>c</sup>	27.80±1.64 <sup>b</sup>	47.20±1.48 <sup>c</sup>	24.20±0.84 <sup>b</sup>	24.60±2.24 <sup>b</sup>
15% Okara Diet	21.00±1.58 <sup>b</sup>	25.20±2.39 <sup>b</sup>	42.00±1.58 <sup>b</sup>	23.80±2.25 <sup>b</sup>	23.40±3.05 <sup>b</sup>
			PANCREAS		
Normal Control	30.20±0.84 <sup>c</sup>	32.60±1.14 <sup>c</sup>	54.40±2.97 <sup>c</sup>	34.80±1.30 <sup>c</sup>	35.00±2.74 <sup>c</sup>
Negative Control	11.40±1.14 <sup>a</sup>	12.60±3.05 <sup>a</sup>	23.80±2.39 <sup>a</sup>	12.80±1.92 <sup>a</sup>	11.60±1.82 <sup>a</sup>
Positive Control	23.80±1.30 <sup>b</sup>	23.20±1.79 <sup>b</sup>	45.20±2.86 <sup>b</sup>	25.60±2.30 <sup>b</sup>	23.20±2.86 <sup>b</sup>
15% Okara Diet	23.40±1.82 <sup>b</sup>	24.40±2.41 <sup>b</sup>	43.00±2.65 <sup>b</sup>	23.00±2.55 <sup>b</sup>	22.60±2.61 <sup>b</sup>

Means with the same alphabet as superscript within each column variable are non-significantly ( $p > 0.05$ ). Abbreviations denote SOD: Superoxide dismutase, GSH: reduced glutathione, GST: Glutathione-S-transfer, GPX: Glutathione peroxidase.

i) Histology of the pancreatic tissue

Plate I to III demonstrates the histological changes in Pancreatic, Liver, and Kidney tissues of four (4) groups at the end of the experimental period. (A) Section of the pancreas from normal control, with no visible lesions, observed. (B) Section of the pancreas from negative control, with a severe peritubular cellular infiltration. (C) Section of the pancreas from positive control, with no visible lesions, observed. (D) Section of the pancreas from 15% Okara diet, with no visible

lesions, observed. (E) Section of the liver from normal control, with no visible lesions, observed. (F) Section of the liver from negative control, with random foci of single-cell hepatocellular necrosis. There is moderate Kupffer cell hyperplasia. (G) Section of the liver from positive control and (H) Section of the liver from 15% okara supplemented diet showed no visible lesions. Fig I to L section of the kidney showed no visible lesions for all groups.




Plate I: Showing the histological section of Pancreatic Tissue






Plate II: Showing the histological section of Liver Tissue




Plate III: Showing the histological section of Kidney Tissue

#### IV. DISCUSSION

Diabetes mellitus is a serious health concern worldwide, and it is becoming the third most lethal disease of human and has continued to be on a rapid rise [24, 25]. In this light, it is imperative for an unrelenting research on evaluation and validation of nutraceutical potentials of plant food for the management of diabetes mellitus. Therefore, the present study sought to carefully examine the role of Okara supplemented diet on diabetic male Wistar rats.

Polyphagia is a condition characterized by an increased appetite leading to an increase in feed/food intake. It represents the initial signs of diabetes in humans as well as in experimental models [26, 7]. Owing to this finding, of course, our study demonstrated (table 2) that after diabetes induction with 50mg/kg streptozotocin from day 8 - day 15, the cumulative feed intake of the experimental groups were significantly increased  $p < 0.05$  vis-a-vis the normal control, and this may be as a result of the low levels of leptin; a critical signaling molecule in the hypothalamus influencing appetite and satiety [27]. Correspondingly, streptozotocin toxicity has been demonstrated to elicit a low level of leptin, and during uncontrolled Type 1 diabetes, plasma leptin levels rapidly fall whereas food intake increases [28,29]. However, 15% okara supplemented diets fed group from day 36 to day 43 showed no significant difference  $p > 0.05$  in cumulative feed intake relative to the normal control, and it may be attributed to the hypoglycemic potency of okara diet as seen in figure

2 and apparently, restoring the health status of the rats. Our result corroborates the finding of [7].

Streptozotocin-induced diabetes has been demonstrated to be associated with a severe reduction in body weight, perhaps, due to the degradation or loss of structural proteins that are clearly established to contribute to body weight gain [30]. Correspondingly, our study (figure 1) demonstrated that diabetes status was associated with a reduction in body weight as seen with the diabetic groups after an intraperitoneal injection of 50mg/kg streptozotocin. However, 15% okara supplemented diet feeding was significantly able to restore there rats body weight almost back to normal vis-à-vis negative control and this may be due to an improvement in diabetic status and other related abnormalities.

Diabetes mellitus is a metabolic disorder associated with an increased blood sugar levels, and of course, the result of our study figure 2, demonstrated a significant blood sugar elevation after intraperitoneal injection of 50mg/kg streptozotocin. However, 6mg/kg glibenclamide treatment and 15% okara diet supplemented diet significantly lowered the blood sugar levels, and the hypoglycemic ability of okara diet may be attributed to its high fiber content. High dietary fiber has been demonstrated to be beneficial, long lasting, and clinically relevant both in types 1 and type 2 diabetes [10] and this reports corroborate the findings of [31, 14].

To further confirm the hypoglycemic ability of okara diet, glucose-6-phosphate dehydrogenase, and glycated hemoglobin levels were evaluated (table 3).

Glucose-6-phosphate dehydrogenase (G6PD), an enzyme that catalyzes the first step in the hexose monophosphate (HMP) shunt an alternative pathway for the catabolism of glucose to yield pentose sugar, and Glycated hemoglobin (HbA1c) formed in a non-enzymatic pathway by hemoglobin's normal exposure to high plasma glucose levels [32]. As reported by [32], both markers are good predictors of diabetes. In this light, our study revealed that 15% okara diet supplemented diet restored the levels of G6PD and HbA1c vis-à-vis the negative control. Therefore, okara diet is a potent dietary agent for the management of diabetes.

Diabetic dyslipidemia shows high levels of plasma cholesterol (CHOL), triglyceride (TRIG), LDL-cholesterol (LDL), and low HDL-cholesterol (HDL) concentrations [33]. Similarly, alterations in lipid metabolism can cause lipotoxicity, which can further exacerbate diabetic complications [34]. Also, a high level of serum triglycerides, and a low level of High-Density Lipoprotein (HDL) are listed among the constellation for the medical conditions related to metabolic syndrome [35]. Of course, the result of the present study (table 4) revealed that the diabetic group (negative control) significantly  $p < 0.05$  had an elevated level of CHOL, TRIG, LDL and a reduced level of HDL relative to the normal control. Conversely, 15% okara supplemented diet feeding significantly normalized the lipid triad and hence may have also improved the diabetic condition of the rats. Additionally, our result corroborates the finding of [13, 14, 36].

Markers used to determine toxic effects of administered foreign substances to experimental animals are enzymes activities. Liver function enzyme ALP, is a membrane-bound enzyme meanwhile, ALT, and AST are cytosolic enzymes [37]. Therefore, high levels of ALP, ALT and AST respectively in the serum, are indicators of cell membrane permeability and a significant degree of damage to the liver [37]. Streptozotocin, a diabetogenic agent is associated with some degree of liver damage by several studies [38, 39]. In this light, of course, our result presented in Table 5 demonstrated that the levels of liver function biomarkers were significantly elevated in negative control which was exposed to 50mg/kg intraperitoneal injection of STZ relative to normal control. However, 15% okara diet supplementation potentiated a significant reduction in liver function biomarkers and this result suggests that some components of okara, namely; dietary fiber, dietary bioflavonoids, and isoflavones, could be associated with its ability in maintaining liver function.

Furthermore, one of the huge concerns of DM is its related complications, which can affect multiple vital organ systems [40, 41]. Creatinine, Urea, and electrolyte are selected indices of kidney function [42]. In this light, of course, the result of the present study table 6,

underscored the favorable role of 15% okara diet supplementation in abrogating renal dysfunction induced by exposure to streptozotocin, as there was a significant reduction  $p < 0.05$  in markers of kidney function vis-à-vis the negative control.

Antioxidants are key players for the investigation of oxidant stress-related diabetic pathologies, and the activities of the antioxidant enzymes catalase, superoxide dismutase, and glutathione peroxidase has been demonstrated to be reduced in diabetic conditions [43]. Correspondingly, DM is associated with an increased free radicals formation, and a decreased antioxidant capacity, consequently resulting to oxidative stress and a damage of cell components [44].

The result of the present study table 7, demonstrated that the negative control which remained untreated after 50mg/kg intraperitoneal injection of streptozotocin showed a significant decrease  $p < 0.05$  in levels of antioxidant enzymes CAT, SOD, GSH, GST, and GPX relative to the normal control for pancreas, liver and kidney respectively. The result is in tandem with the reports that kidney antioxidant enzyme activity declines in STZ induced animals as a consequence of the oxidative stress elicited by STZ [45]. Oxidative stress induced by streptozotocin (STZ) results to pancreatic beta cell damage [46], and a decline in the levels of liver antioxidant enzyme [47]. Interestingly, 15% okara supplemented diet caused a significant increase  $p < 0.05$  in antioxidant enzyme levels vis-à-vis negative control for all organs and this activity may be as a result of its composition which corresponds with the report of [48]; reported that, Okara contains phenolic compounds (106.7 mg gallic acid equivalents (GAE)/100 g) and flavonoids (32.7 mg quercetin equivalents/100 g) and showed antioxidant activity.

The histological observation of the pancreas figure A to D as contained in plate I for this study, revealed that the untreated group after 50mg/kg STZ injection (Negative control) had a severe a peritubular cellular infiltration. Perhaps, as a result of STZ diabetogenic action, by a direct irreversible damage to the pancreatic beta cells, this leads to degranulation, and loss of capacity to secrete insulin [49]. Correspondingly, the prevalence of diabetes mellitus is positively correlated with fatty infiltration of the pancreas [50]. However, the pancreatic tissue of the 15% okara supplemented diet fed group showed no visible lesions, and this highlights its ameliorative potency in the management of diabetes mellitus. The histological observation of the liver figure E to H, plate II shows that negative control (F) had random foci of single-cell hepatocellular necrosis, but this was reversed by 15% okara supplemented diet (H) as there was no visible lesion observed. However, the histological observation of the kidney figure I to L, plate III showed no visible lesion for all groups contrary to the findings of [45] that histological observation of the kidney exposed to STZ was necrotic.



## V. CONCLUSION

A poor dietary habit has been demonstrated to be one of the key players in the development of diabetes mellitus, and a diet rich in dietary fiber has been highlighted to be a potent candidate for the management of DM. Thus, the result of our study shows that Okara diet; perhaps an excellent nutraceutical aids weight reduction, lower blood sugar and glycated hemoglobin levels and maintains a healthy level of lipid profile, liver, kidney, and antioxidant enzyme biomarkers. Conclusively, we recommend a supplementation of food with Okara.

### Authors Contributions

Nwozo Sarah Onyenibe contributions to study were; conceptualized of the study, preparation of study design, supervision of the study, proofread and revised the study. Ikpeme Grace Edet contributed to the study in the area of carry out experimentation, co-preparation of study design, collection of experimental data and reporting and revision of work. Nwawuba Stanley Udogadi contributed to the study by analysis and interpretation of data, preparation of manuscript and revision of the manuscript. All authors have approved the submitted version and agrees to be personally accountable for the authors contributions.

### Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this manuscript.

## REFERENCES RÉFÉRENCES REFERENCIAS

1. <sup>a</sup>Nwozo, S. O.; Modeme, T. E.; Nwawuba, S. U. Evaluation of Momordica charantia, Boerhaavia diffusa and Cotreatment on Streptozotocin induced Diabetes in Male Wistar Rats. *IJBS* 2018, 14(2), 66-73. Available online: URL <http://www.ijbs.org/User/ContentFullText.aspx?VolumeNO=14&StartPage=66&Type=pdf> (accessed on 18<sup>th</sup> December 2018)
2. <sup>a</sup>Nwawuba, S. U.; Nwozo, S. O.; Mohammed, K. A. Dietary Management of Diabetes Mellitus with Focus on Nigeria. *IJDR* 2019, 2(1), 26-32. Available online: URL <http://www.ghrnet.org/index.php/ijhr/article/view/2493> (accessed on 29th May 2019)
3. <sup>a</sup>Nwozo, S. O.; Nyam, A. N.; Nwawuba, S. U.; Olukotun, O. I. Hypoglycemic and Antioxidant Capacity of Curcuma Longa and Viscum Album in Alloxan Induced Diabetic Male Wistar Rats. *IJDE* 2019, 4(1), 26-34. Available online: URL <http://www.sciencepublishinggroup.com/ijjde> (accessed on 07th May 2019)
4. World Health Organization. Global Report on Diabetes. 2016, ISBN, 978, 88. Available online: URL [https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257\\_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf?sequence=1) (accessed on 07<sup>th</sup> June 2019)

5. <sup>b</sup>Nwawuba, S. U.; Monago, C. C.; Mejulu, K. C. Ameliorative effect of aqueous seed extract of delonixregia on hyperglycemia, liver function and lipid profile levels in Streptozotocin induced Diabetic Male wistar rats. *Pharm Pharmacolnt J* 2019, 7(3), 126–131. Available online: URL <https://medcraveonline.com/PPIJ/PPIJ-07-00242.pdf> (accessed on 10th June 2019)
6. Chikezie, P. C.; Ojjako, O. A.; Nwufu, K. C. Overview of Anti-Diabetic Medicinal Plants: The Nigerian Research Experience. *J Diabetes Metab.* 2015, 6(6), 1–7. Available online: URL <https://www.omicsonline.org/open-access/overview-of-antidiabetic-medicinal-plants-the-nigerian-research-experience-2155-6156-1000546.php?aid=53380> (Accessed on 07th June 2019)
7. Ismaiel, M.; Hong, Y.; Min, Cui. Evaluation of High Fibers Okara and Soybean Bran as Functional Supplements for Mice with Experimentally Induced Type 2 Diabetes. *Pol. J. Food Nutr. Sci* 2017, 67(4), 327–337. Available online: URL <https://content.sciendo.com/view/journals/pjfn/67/4/article-p327.xml> (Accessed on 9th June 2019)
8. Dueñas, M.; Hernández, T.; Robredo, S.; Lamparski, G.; Estrella, I.; Muñoz, R. Bioactive phenolic compounds of soybean (*Glycinemax* cv. Merit): modifications by different microbiological fermentations. *Pol. J. Food Nutr. Sci* 2012, 62, 241–250. Available online: URL <https://content.sciendo.com/view/journals/pjfn/62/4/article-p241.xml> (Accessed on 7th June 2019)
9. Nuttall, F. Q. Dietary fiber in the management of diabetes. *Diabetes*.1993, 42(4), 503-8. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/8384131> (Accessed on 07th June 2019)
10. Giacco, R.; Clemente, G.; Riccardi, G. Dietary fibre in treatment of diabetes: myth or reality? *Digestive and Liver Disease (Elsevier)*, 2002, 34 (Suppl 2), S140–S144. Available online: URL <https://www.sciencedirect.com/science/article/pii/S1590865802801827> (Accessed on 05<sup>th</sup> June 2019)
11. Mateos-Aparicio, I.; Mateos-Peinado, C; Rupérez, P. “High hydrostatic pressure improves the functionality of dietary fibre in okara by-product from soybean”. *IFSET* 2010, 11(3), 445–450. Available online: URL <http://www.sciencedirect.com/science/journal/14668564> (Accessed on 05th June 2019)
12. Préstamo, G.; Rupérez, P.; Espinosa–Martos, I.; Villanueva, M. J.; Lasunción, M. A. The effects of okara on rat growth, cecal fermentation, and serum lipids. *Eur. Food Res. Technol* 2007, 225, 925–928. Available online: URL <https://www.researchgate.net/publication/225557986> (Accessed on 9th June 2019)
13. Surel, O.; Couplet, B. Influence of the dehydration process on active compounds of okara during its fractionation. *J. Sci. Food Agric* 2005, 85,



- 1343–1349. Available online: URL <http://lib3.dss.gov.th/fulltext/Journal/J.Sci.Food%20and%20Agri/2005v85/no.8/2005v85no8p1343-1349.pdf> (Accessed on 05th June 2019)
14. Eze, O. F.; Ani, J. C.; Obasi, N. E. Dietary fibre potentials of some selected flours and their effect on blood glucose and serum cholesterol reduction. (EJFST) EA Journals 2014, 2(2), 1-12. Available online: URL <http://www.eajournals.org/wp-content/uploads/Dietary-Fibre-Potentials-of-Some-Selected-Flours-and-Their-Effect-on-Blood-Glucose-and-Serum-Cholesterol-Reduction.pdf> (Accessed on 5<sup>th</sup> June 2019)
  15. Matsumoto, K; Yutaka, W.; Shin-ichiro, Y. Okara, Soybean Residue, Prevents Obesity in a Diet-Induced Murine Obesity Model. Bioscience, Biotechnology, and Biochemistry.2007, 71(3), 720-727. Available online: URL <https://www.tandfonline.com/doi/abs/10.1271/bbb.60563> (Accessed on 07th June 2019)
  16. AOAC Official Methods of Analysis, Association of Official Analytical Chemists, 1995, 16th edition Washington DC.
  17. Azahar, M.A.; Al-naqeb, G.; Hasan, M.; Adam, A. Hypoglycemic effect of Octomelessumatrana aqueous extract in streptozotocin-induced diabetic rats and its molecular mechanisms. Asian Pac J Trop Med. 2012, 5(11), 875–881. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/23146801> (Accessed on 09th June 2019)
  18. Richmond, W. Preparation and properties of a cholesterol oxidase from *Nocardia* specie and its application to the enzymatic assay of total cholesterol in serum. Clinical Chemistry 1973, 19(12), 1350-6. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/4757363> (Accessed on 7th June 2019)
  19. Misra, H. P.; Fridovich, I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem. 1972, 247, 3170-3175. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/4623845> (Accessed on 7th June 2019)
  20. Sinha, A. K. Colrimetric assay of catalase. Anal Biochem 1972, 47, 389-394. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/4556490> (Accessed on 7th June 2019)
  21. Beutler, E.; Duron, O.; Kelly, B.M. Improved method for the determination of blood glutathione. J. Lab Clin Med. 1963, 61, 882-888. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/13967893> (Accessed on 7th July 2019)
  22. Habig, W. H.; Pabst, M. J.; Jakoby, W. B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974, 249, 7130-7139. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/4436300> (Accessed on 05th July 2019)
  23. Rotruck, J. T.; Pope, A. L.; Ganther, H. E.; Swanson, A. B.; Hafeman, D. G.; Hoekstra, W. G. Selenium: Biochemical role as a component of glutathione peroxidase. Science. 1973, 179, 588-90. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/4686466> (Accessed on 09th June 2019)
  24. Sani, F. A.; Atiku, M. K.; Imam, A. A. Effect of oral administration of Aqueous leaf extract of *Momordica charantia* (bitter melon) on serum glucose, and lipid profile in Alloxan-induced Diabetic Rats. BAJOPAS 2015, 8(2), 170–174. Available online: URL <https://www.ajol.info/index.php/bajopas/article/view/136646> (Accessed on 5th June 2019)
  25. Ogbonnia, S. O.; Odimegu, J. I.; Enwuru, V. N. Evaluation of hypoglycemic and hypolipidemic effects of ethanolic extracts of *Treulia Africana* Decne and *Bryopyllum pinntum* Lam. and their mixture on streptozotocin (STZ) –induced diabetic rats. Afr J Biotech 2008, 7(15), 2535-2539. Available online: URL <http://www.academicjournals.org/AJB> (Accessed on 5th June 2019)
  26. Lim, S. I.; Lee, B. Y. Anti-diabetic effect of material fermented using rice bran and soybean as the main ingredient by *Bacillus* sp. J. Korean Soc. Appl. Biol. Chem 2010, 53: 222–229. Available online: URL <https://link.springer.com/article/10.3839/jksabc.2010.035> (Accessed on 5th June 2019)
  27. Ravipati, S.; Rajkumar, B. Role of Leptin in Diabetes Mellitus. Indian Journal of Fundamental and Applied Life Sciences, 2011, 1(2), 209-214. Available online: URL <http://www.cibtech.org/jls.htm> (Accessed on 5th 2019)
  28. Gülen, S.; Dinçer, S. Effects of leptin on oxidative stress in healthy and Streptozotocin-induced diabetic rats. Mol Cell Biochem, 2007, 302(1-2), 59-65. Available online: URL <https://www.researchgate.net/publication/6483345> (Accessed on 5th June 2019)
  29. Sindelar, D. K.; Havel, P. J.; Seeley, R. J.; Wilkinson, C. W.; Woods, S. C.; Schwartz, M. W. Low plasma leptin levels contribute to diabetic hyperphagia in rats. Diabetes 1999, 48(6), 1275-80. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/10342816> (Accessed on 3rd June 2019)
  30. Li F.; Zhang, Y.; Zhong, Z. Antihyperglycemic effect of *Ganoderma lucidum* polysaccharides on streptozotocin-induced diabetic mice. Int. J. Mol. Sci 2011, 12, 6135–6145. Available online: URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189773/> (Accessed on 3<sup>rd</sup> June 2019)
  31. Lu, F.; Liu, Y.; Li, B. Okara dietary fiber and hypoglycemic effect of okara foods. Bioact. Carbohydr. Diet. Fibre 2013, 2, 126–132. Available

- online: URL <https://pubag.nal.usda.gov/catalog/5359622> (Accessed on 3rd June 2019)
32. <sup>b</sup>Nwozo, S. O.; Nwawuba, S. U. Ameliorative Potentials of *Cyperus Esculentus* Oil on Type 2 Diabetes Induced by High Fat Diet and Low Dose Streptozotocin in Male Wistar Rats. *IJDR* 2019, 2(1), 33-38 Available online: URL: <http://www.ghrnet.org/index.php/ijhr/article/view/2494> (Accessed on 29th May 2019)
  33. Mooradian, A. D. Dyslipidemia in type 2 diabetes mellitus. *Nat Clin Pract Endocrinol Metab* 2009, 5(3), 150-9. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/19229235> (Accessed on 3rd June 2019)
  34. Chang, C. L.; Lin, Y.; Bartolome, A. P.; Chen, Y. C.; Chiu, S. C.; Yang, W. C. Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compounds. *Evid Based Complement Alternat Med* 2013, 378657. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/23662132> (accessed on 6th June 2019)
  35. <sup>b</sup>Nwozo, S. O.; Adeneye, D. A.; Nwawuba, S. U. Effect of *Solanium melongena* fruits supplemented diet on hyperglycemia, overweight, liver function and dyslipidemia in male New Zealand rabbits fed high fat and sucrose diet. *Integr Obesity Diabetes* 2018, 4(3), 1-5. Available online: URL <https://www.oatext.com/effect-of-solanium-melongena-fruits-supplemented-diet-on-hyperglycemia-overweight-liver-function-and-dyslipidemia-in-male-new-zealand-rabbits-fed-high-fat-and-sucrose-diet.php> (Accessed on 7th June 2019)
  36. Elreffaei-Wael, H. M.; Eman, M.; Rageb, M. M.; Masoud, A. H. Biological Evaluation of Okara in Rats Based on Plasma Lipid Profile and Histology. *International Journal of Plant & Soil Science* 2014, 3(6), 507-522. Available online: URL <https://journals.indexcopernicus.com/search/article?articleId=2021998> (Accessed on 5th June 2019)
  37. Nwawuba, S. U.; Okechukwu, F. C. The effect of *Cyperus esculentus* (Tigernut) oil on liver, kidney and hematological biomarkers in low dose streptozotocin and high fat diet exposed male wistar rats. *Int. J. Food Sci. Nutr.* 2018, 3(4), 148-152. Available online: URL <http://www.foodsciencejournal.com/archives/2018/vol3/issue4> (Accessed on 28th JULY 2018)
  38. Afrin, R. S.; Arumugam, V.; Soetikno, R. A.; Thandavarayan, V.; Pitchaimani, V.; Karuppagounder, R.; Sreedhar, M.; Harima, H.; Suzuki, S.; Miyashita, M.; Nomoto, K.; Watanabe, K. Curcumin ameliorates streptozotocin-induced liver damage through modulation of endoplasmic reticulum stress-mediated apoptosis in diabetic rats. *Free Radic. Res.* 2015, 49(3), 279-289. Available online: URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389763/> (Accessed on 5th June 2019)
  39. Omonkhua, A. A.; Adebayo, E. A.; Saliu, J. A.; Ogunwa, T. H.; Adeyelu, T. T. Liver function of Streptozotocin- Induced Diabetic Rats Orally Administered Aqueous Root-Bark Extracts of *Tetrapleuratetraptera* (Taub). *Nig. J. Basic and Appl. Sci.* 2014, 22(3 & 4), 99-106. Available online: URL <https://www.ajol.info/index.php/njbas/article/view/118049> (Accessed on 9th July 2019)
  40. Mohamed, J.; Nazratun, N.A.H.; Zariyantey, A. H.; Budin, S. B. Mechanisms of Diabetes-Induced Liver Damage; The role of oxidative stress and inflammation. *Sultan Qaboos Univ Med J.* 2016, 16(2), e132-e141. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/27226903> (Accessed on 7th June 2019)
  41. Reid, A. E. Non-alcoholic fatty liver disease. In: Feldman M, Friedman L S, Brandt L J, editors. *Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/diagnosis/management.* 8th ed. St Louis, Missouri, USA: Saunders; 2006. pp. 1772-99.
  42. Shivaraj, G.; Prakash, B. D.; Shruthi, S. K.; Vinayak, V. H.; Avinash, A. K.; Sonal, N. V. Markers of renal function tests. *N Am J Med Sci.* 2010, 2(4), 170-173. Available online: URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3354405/> (Accessed on 5th June 2019)
  43. Bajaj, S.; Afreen, K. Antioxidants and diabetes. *Indian J Endocrinol Metab.* 2012, 16 (Suppl 2), S267-S271. Available online: URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603044/> (Accessed on 5th June 2019)
  44. Bashan, N.; Kovsan, J.; Kachko, I.; Ovadia, H.; Rudich, A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. *Physio Rev* 2009, 89:27-71. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/19126754> (Accessed on 5th June 2019)
  45. Gomathi, D.; Kalaiselvi, M.; Ravikumar, G.; Devaki, K.; Uma, C. Evaluation of Antioxidants in the Kidney of Streptozotocin Induced Diabetic Rats. *Ind J ClinBiochem* 2014, 29(2), 221-226. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/24757306> (Accessed on 9th June 2019)
  46. Chis, I. C.; Ungureanu, M. I.; Marton, A.; Simesdrea, R.; Muresan, A.; Postescu, I. D. Antioxidant effects of a grape seed extract in a rat model of diabetes mellitus. *DiabVasc Dis Res.* 2009, 6(3), 200-4. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/20368212> (Accessed on 5th June 2019)
  47. Sheweita, S. A.; Mashaly, S.; Newairy, A. A.; Abdou, H. M.; Eweda, S. M. Changes in Oxidative Stress and Antioxidant Enzyme Activities in Streptozotocin-Induced Diabetes Mellitus in Rats: Role of *Alhagima aurorum* Extracts. *Oxid Med Cell Long.* 2016, Article ID 5264064, 1-8. Available online: URL <http://dx.doi.org/10.1155/2016/5264064> <https://>

www.hindawi.com/journals/omcl/2016/5264064/  
(Accessed 6<sup>th</sup> June 2019)

48. Vital, A.C.P.; Croge, C.; da Silva, D. F. Okara residue as source of antioxidants against lipid oxidation in milk enriched with omega-3 and bioavailability of bioactive compounds after in vitro gastrointestinal digestion. *J Food Sci Technol* 2018, 55(4), 1518-152. Available online: URL <https://www.ncbi.nlm.nih.gov/pubmed/29606766> (Accessed on 6th June 2019)
49. Gu, D.; Arnush, M.; Sarvetnic, N. Endocrine/exocrine intermediate cells in Streptozotocin treated Ins-IFN $\gamma$  transgenic mice. *Pancreas* 1997, 15(3), 246-250. Available online: URL <http://europepmc.org/abstract/MED/9336787> (Accessed on 5th June 2019)
50. Hori, M.; Michihiro, M.; Toshio, I.; Hitoshi, N.; Mami, T. Possible Involvement of Pancreatic Fatty Infiltration in Pancreatic Carcinogenesis. *JOP*. 2016, 17(2), 166-175. Available online: URL <http://pancreas.imedpub.com/possible-involvement-of-pancreatic-fatty-infiltration-in-pancreatic-carcinogenesis.pdf> (Accessed on 20th June 2019)



# GLOBAL JOURNALS GUIDELINES HANDBOOK 2019

---

[WWW.GLOBALJOURNALS.ORG](http://WWW.GLOBALJOURNALS.ORG)

# FELLOWS

## FELLOW OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (FARSM)

Global Journals Incorporate (USA) is accredited by Open Association of Research Society (OARS), U.S.A and in turn, awards "FARSM" title to individuals. The 'FARSM' title is accorded to a selected professional after the approval of the Editor-in-Chief/Editorial Board Members/Dean.



- The "FARSM" is a dignified title which is accorded to a person's name viz. Dr. John E. Hall, Ph.D., FARSS or William Walldroff, M.S., FARSM.

FARSM accrediting is an honor. It authenticates your research activities. After recognition as FARSM, you can add 'FARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and reputation to your name. You may use it on your professional Counseling Materials such as CV, Resume, and Visiting Card etc.

*The following benefits can be availed by you only for next three years from the date of certification:*



FARSM designated members are entitled to avail a 40% discount while publishing their research papers (of a single author) with Global Journals Incorporation (USA), if the same is accepted by Editorial Board/Peer Reviewers. If you are a main author or co-author in case of multiple authors, you will be entitled to avail discount of 10%.

Once FARSM title is accorded, the Fellow is authorized to organize a symposium/seminar/conference on behalf of Global Journal Incorporation (USA). The Fellow can also participate in conference/seminar/symposium organized by another institution as representative of Global Journal. In both the cases, it is mandatory for him to discuss with us and obtain our consent.



You may join as member of the Editorial Board of Global Journals Incorporation (USA) after successful completion of three years as Fellow and as Peer Reviewer. In addition, it is also desirable that you should organize seminar/symposium/conference at least once.

We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.








The FARSM can go through standards of OARS. You can also play vital role if you have any suggestions so that proper amendment can take place to improve the same for the benefit of entire research community.

As FARSM, you will be given a renowned, secure and free professional email address with 100 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.



The FARSM will be eligible for a free application of standardization of their researches. Standardization of research will be subject to acceptability within stipulated norms as the next step after publishing in a journal. We shall depute a team of specialized research professionals who will render their services for elevating your researches to next higher level, which is worldwide open standardization.

The FARSM member can apply for grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A. Once you are designated as FARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria. After certification of all your credentials by OARS, they will be published on your Fellow Profile link on website <https://associationofresearch.org> which will be helpful to upgrade the dignity.



The FARSM members can avail the benefits of free research podcasting in Global Research Radio with their research documents. After publishing the work, (including published elsewhere worldwide with proper authorization) you can upload your research paper with your recorded voice or you can utilize chargeable services of our professional RJs to record your paper in their voice on request.



The FARSM member also entitled to get the benefits of free research podcasting of their research documents through video clips. We can also streamline your conference videos and display your slides/ online slides and online research video clips at reasonable charges, on request.





The FARSM is eligible to earn from sales proceeds of his/her researches/reference/review Books or literature, while publishing with Global Journals. The FARSS can decide whether he/she would like to publish his/her research in a closed manner. In this case, whenever readers purchase that individual research paper for reading, maximum 60% of its profit earned as royalty by Global Journals, will be credited to his/her bank account. The entire entitled amount will be credited to his/her bank account exceeding limit of minimum fixed balance. There is no minimum time limit for collection. The FARSM member can decide its price and we can help in making the right decision.

The FARSM member is eligible to join as a paid peer reviewer at Global Journals Incorporation (USA) and can get remuneration of 15% of author fees, taken from the author of a respective paper. After reviewing 5 or more papers you can request to transfer the amount to your bank account.



## MEMBER OF ASSOCIATION OF RESEARCH SOCIETY IN MEDICAL (MARSM)

The ' MARSM ' title is accorded to a selected professional after the approval of the Editor-in-Chief / Editorial Board Members/Dean.

The “MARSM” is a dignified ornament which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., MARSM or William Walldroff, M.S., MARSM.



MARSM accrediting is an honor. It authenticates your research activities. After becoming MARSM, you can add 'MARSM' title with your name as you use this recognition as additional suffix to your status. This will definitely enhance and add more value and repute to your name. You may use it on your professional Counseling Materials such as CV, Resume, Visiting Card and Name Plate etc.

*The following benefits can be availed by you only for next three years from the date of certification.*



MARSM designated members are entitled to avail a 25% discount while publishing their research papers (of a single author) in Global Journals Inc., if the same is accepted by our Editorial Board and Peer Reviewers. If you are a main author or co-author of a group of authors, you will get discount of 10%.

As MARSM, you will be given a renowned, secure and free professional email address with 30 GB of space e.g. [johnhall@globaljournals.org](mailto:johnhall@globaljournals.org). This will include Webmail, Spam Assassin, Email Forwarders, Auto-Responders, Email Delivery Route tracing, etc.





We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



The MARSM member can apply for approval, grading and certification of standards of their educational and Institutional Degrees to Open Association of Research, Society U.S.A.



Once you are designated as MARSM, you may send us a scanned copy of all of your credentials. OARS will verify, grade and certify them. This will be based on your academic records, quality of research papers published by you, and some more criteria.

It is mandatory to read all terms and conditions carefully.



## AUXILIARY MEMBERSHIPS

### Institutional Fellow of Open Association of Research Society (USA) - OARS (USA)

Global Journals Incorporation (USA) is accredited by Open Association of Research Society, U.S.A (OARS) and in turn, affiliates research institutions as “Institutional Fellow of Open Association of Research Society” (IFOARS).



The “FARSC” is a dignified title which is accorded to a person’s name viz. Dr. John E. Hall, Ph.D., FARSC or William Walldroff, M.S., FARSC.

The IFOARS institution is entitled to form a Board comprised of one Chairperson and three to five board members preferably from different streams. The Board will be recognized as “Institutional Board of Open Association of Research Society”-(IBOARS).

*The Institute will be entitled to following benefits:*



The IBOARS can initially review research papers of their institute and recommend them to publish with respective journal of Global Journals. It can also review the papers of other institutions after obtaining our consent. The second review will be done by peer reviewer of Global Journals Incorporation (USA) The Board is at liberty to appoint a peer reviewer with the approval of chairperson after consulting us.

The author fees of such paper may be waived off up to 40%.

The Global Journals Incorporation (USA) at its discretion can also refer double blind peer reviewed paper at their end to the board for the verification and to get recommendation for final stage of acceptance of publication.



The IBOARS can organize symposium/seminar/conference in their country on behalf of Global Journals Incorporation (USA)-OARS (USA). The terms and conditions can be discussed separately.


The Board can also play vital role by exploring and giving valuable suggestions regarding the Standards of “Open Association of Research Society, U.S.A (OARS)” so that proper amendment can take place for the benefit of entire research community. We shall provide details of particular standard only on receipt of request from the Board.



The board members can also join us as Individual Fellow with 40% discount on total fees applicable to Individual Fellow. They will be entitled to avail all the benefits as declared. Please visit Individual Fellow-sub menu of GlobalJournals.org to have more relevant details.



We shall provide you intimation regarding launching of e-version of journal of your stream time to time. This may be utilized in your library for the enrichment of knowledge of your students as well as it can also be helpful for the concerned faculty members.



After nomination of your institution as “Institutional Fellow” and constantly functioning successfully for one year, we can consider giving recognition to your institute to function as Regional/Zonal office on our behalf. The board can also take up the additional allied activities for betterment after our consultation.

**The following entitlements are applicable to individual Fellows:**

Open Association of Research Society, U.S.A (OARS) By-laws states that an individual Fellow may use the designations as applicable, or the corresponding initials. The Credentials of individual Fellow and Associate designations signify that the individual has gained knowledge of the fundamental concepts. One is magnanimous and proficient in an expertise course covering the professional code of conduct, and follows recognized standards of practice.



Open Association of Research Society (US)/ Global Journals Incorporation (USA), as described in Corporate Statements, are educational, research publishing and professional membership organizations. Achieving our individual Fellow or Associate status is based mainly on meeting stated educational research requirements.

Disbursement of 40% Royalty earned through Global Journals : Researcher = 50%, Peer Reviewer = 37.50%, Institution = 12.50% E.g. Out of 40%, the 20% benefit should be passed on to researcher, 15 % benefit towards remuneration should be given to a reviewer and remaining 5% is to be retained by the institution.



We shall provide print version of 12 issues of any three journals [as per your requirement] out of our 38 journals worth \$ 2376 USD.

**Other:**

**The individual Fellow and Associate designations accredited by Open Association of Research Society (US) credentials signify guarantees following achievements:**

- The professional accredited with Fellow honor, is entitled to various benefits viz. name, fame, honor, regular flow of income, secured bright future, social status etc.





- In addition to above, if one is single author, then entitled to 40% discount on publishing research paper and can get 10% discount if one is co-author or main author among group of authors.
- The Fellow can organize symposium/seminar/conference on behalf of Global Journals Incorporation (USA) and he/she can also attend the same organized by other institutes on behalf of Global Journals.
- The Fellow can become member of Editorial Board Member after completing 3yrs.
- The Fellow can earn 60% of sales proceeds from the sale of reference/review books/literature/publishing of research paper.
- Fellow can also join as paid peer reviewer and earn 15% remuneration of author charges and can also get an opportunity to join as member of the Editorial Board of Global Journals Incorporation (USA)
- • This individual has learned the basic methods of applying those concepts and techniques to common challenging situations. This individual has further demonstrated an in-depth understanding of the application of suitable techniques to a particular area of research practice.

**Note :**

//

- In future, if the board feels the necessity to change any board member, the same can be done with the consent of the chairperson along with anyone board member without our approval.
- In case, the chairperson needs to be replaced then consent of 2/3rd board members are required and they are also required to jointly pass the resolution copy of which should be sent to us. In such case, it will be compulsory to obtain our approval before replacement.
- In case of “Difference of Opinion [if any]” among the Board members, our decision will be final and binding to everyone.

//



# PREFERRED AUTHOR GUIDELINES

## **We accept the manuscript submissions in any standard (generic) format.**

We typeset manuscripts using advanced typesetting tools like Adobe In Design, CorelDraw, TeXnicCenter, and TeXStudio. We usually recommend authors submit their research using any standard format they are comfortable with, and let Global Journals do the rest.

Alternatively, you can download our basic template from <https://globaljournals.org/Template>

Authors should submit their complete paper/article, including text illustrations, graphics, conclusions, artwork, and tables. Authors who are not able to submit manuscript using the form above can email the manuscript department at [submit@globaljournals.org](mailto:submit@globaljournals.org) or get in touch with [chiefeditor@globaljournals.org](mailto:chiefeditor@globaljournals.org) if they wish to send the abstract before submission.

## BEFORE AND DURING SUBMISSION

Authors must ensure the information provided during the submission of a paper is authentic. Please go through the following checklist before submitting:

1. Authors must go through the complete author guideline and understand and *agree to Global Journals' ethics and code of conduct*, along with author responsibilities.
2. Authors must accept the privacy policy, terms, and conditions of Global Journals.
3. Ensure corresponding author's email address and postal address are accurate and reachable.
4. Manuscript to be submitted must include keywords, an abstract, a paper title, co-author(s') names and details (email address, name, phone number, and institution), figures and illustrations in vector format including appropriate captions, tables, including titles and footnotes, a conclusion, results, acknowledgments and references.
5. Authors should submit paper in a ZIP archive if any supplementary files are required along with the paper.
6. Proper permissions must be acquired for the use of any copyrighted material.
7. Manuscript submitted *must not have been submitted or published elsewhere* and all authors must be aware of the submission.

## **Declaration of Conflicts of Interest**

It is required for authors to declare all financial, institutional, and personal relationships with other individuals and organizations that could influence (bias) their research.

## POLICY ON PLAGIARISM

Plagiarism is not acceptable in Global Journals submissions at all.

Plagiarized content will not be considered for publication. We reserve the right to inform authors' institutions about plagiarism detected either before or after publication. If plagiarism is identified, we will follow COPE guidelines:

Authors are solely responsible for all the plagiarism that is found. The author must not fabricate, falsify or plagiarize existing research data. The following, if copied, will be considered plagiarism:

- Words (language)
- Ideas
- Findings
- Writings
- Diagrams
- Graphs
- Illustrations
- Lectures



- Printed material
- Graphic representations
- Computer programs
- Electronic material
- Any other original work

## AUTHORSHIP POLICIES

Global Journals follows the definition of authorship set up by the Open Association of Research Society, USA. According to its guidelines, authorship criteria must be based on:

1. Substantial contributions to the conception and acquisition of data, analysis, and interpretation of findings.
2. Drafting the paper and revising it critically regarding important academic content.
3. Final approval of the version of the paper to be published.

### Changes in Authorship

The corresponding author should mention the name and complete details of all co-authors during submission and in manuscript. We support addition, rearrangement, manipulation, and deletions in authors list till the early view publication of the journal. We expect that corresponding author will notify all co-authors of submission. We follow COPE guidelines for changes in authorship.

### Copyright

During submission of the manuscript, the author is confirming an exclusive license agreement with Global Journals which gives Global Journals the authority to reproduce, reuse, and republish authors' research. We also believe in flexible copyright terms where copyright may remain with authors/employers/institutions as well. Contact your editor after acceptance to choose your copyright policy. You may follow this form for copyright transfers.

### Appealing Decisions

Unless specified in the notification, the Editorial Board's decision on publication of the paper is final and cannot be appealed before making the major change in the manuscript.

### Acknowledgments

Contributors to the research other than authors credited should be mentioned in Acknowledgments. The source of funding for the research can be included. Suppliers of resources may be mentioned along with their addresses.

### Declaration of funding sources

Global Journals is in partnership with various universities, laboratories, and other institutions worldwide in the research domain. Authors are requested to disclose their source of funding during every stage of their research, such as making analysis, performing laboratory operations, computing data, and using institutional resources, from writing an article to its submission. This will also help authors to get reimbursements by requesting an open access publication letter from Global Journals and submitting to the respective funding source.

## PREPARING YOUR MANUSCRIPT

Authors can submit papers and articles in an acceptable file format: MS Word (doc, docx), LaTeX (.tex, .zip or .rar including all of your files), Adobe PDF (.pdf), rich text format (.rtf), simple text document (.txt), Open Document Text (.odt), and Apple Pages (.pages). Our professional layout editors will format the entire paper according to our official guidelines. This is one of the highlights of publishing with Global Journals—authors should not be concerned about the formatting of their paper. Global Journals accepts articles and manuscripts in every major language, be it Spanish, Chinese, Japanese, Portuguese, Russian, French, German, Dutch, Italian, Greek, or any other national language, but the title, subtitle, and abstract should be in English. This will facilitate indexing and the pre-peer review process.

The following is the official style and template developed for publication of a research paper. Authors are not required to follow this style during the submission of the paper. It is just for reference purposes.



### ***Manuscript Style Instruction (Optional)***

- Microsoft Word Document Setting Instructions.
- Font type of all text should be Swis721 Lt BT.
- Page size: 8.27" x 11", left margin: 0.65, right margin: 0.65, bottom margin: 0.75.
- Paper title should be in one column of font size 24.
- Author name in font size of 11 in one column.
- Abstract: font size 9 with the word "Abstract" in bold italics.
- Main text: font size 10 with two justified columns.
- Two columns with equal column width of 3.38 and spacing of 0.2.
- First character must be three lines drop-capped.
- The paragraph before spacing of 1 pt and after of 0 pt.
- Line spacing of 1 pt.
- Large images must be in one column.
- The names of first main headings (Heading 1) must be in Roman font, capital letters, and font size of 10.
- The names of second main headings (Heading 2) must not include numbers and must be in italics with a font size of 10.

### ***Structure and Format of Manuscript***

The recommended size of an original research paper is under 15,000 words and review papers under 7,000 words. Research articles should be less than 10,000 words. Research papers are usually longer than review papers. Review papers are reports of significant research (typically less than 7,000 words, including tables, figures, and references)

A research paper must include:

- a) A title which should be relevant to the theme of the paper.
- b) A summary, known as an abstract (less than 150 words), containing the major results and conclusions.
- c) Up to 10 keywords that precisely identify the paper's subject, purpose, and focus.
- d) An introduction, giving fundamental background objectives.
- e) Resources and techniques with sufficient complete experimental details (wherever possible by reference) to permit repetition, sources of information must be given, and numerical methods must be specified by reference.
- f) Results which should be presented concisely by well-designed tables and figures.
- g) Suitable statistical data should also be given.
- h) All data must have been gathered with attention to numerical detail in the planning stage.

Design has been recognized to be essential to experiments for a considerable time, and the editor has decided that any paper that appears not to have adequate numerical treatments of the data will be returned unrefereed.

- i) Discussion should cover implications and consequences and not just recapitulate the results; conclusions should also be summarized.
- j) There should be brief acknowledgments.
- k) There ought to be references in the conventional format. Global Journals recommends APA format.

Authors should carefully consider the preparation of papers to ensure that they communicate effectively. Papers are much more likely to be accepted if they are carefully designed and laid out, contain few or no errors, are summarizing, and follow instructions. They will also be published with much fewer delays than those that require much technical and editorial correction.

The Editorial Board reserves the right to make literary corrections and suggestions to improve brevity.



## FORMAT STRUCTURE

***It is necessary that authors take care in submitting a manuscript that is written in simple language and adheres to published guidelines.***

All manuscripts submitted to Global Journals should include:

### **Title**

The title page must carry an informative title that reflects the content, a running title (less than 45 characters together with spaces), names of the authors and co-authors, and the place(s) where the work was carried out.

### **Author details**

The full postal address of any related author(s) must be specified.

### **Abstract**

The abstract is the foundation of the research paper. It should be clear and concise and must contain the objective of the paper and inferences drawn. It is advised to not include big mathematical equations or complicated jargon.

Many researchers searching for information online will use search engines such as Google, Yahoo or others. By optimizing your paper for search engines, you will amplify the chance of someone finding it. In turn, this will make it more likely to be viewed and cited in further works. Global Journals has compiled these guidelines to facilitate you to maximize the web-friendliness of the most public part of your paper.

### **Keywords**

A major lynchpin of research work for the writing of research papers is the keyword search, which one will employ to find both library and internet resources. Up to eleven keywords or very brief phrases have to be given to help data retrieval, mining, and indexing.

One must be persistent and creative in using keywords. An effective keyword search requires a strategy: planning of a list of possible keywords and phrases to try.

Choice of the main keywords is the first tool of writing a research paper. Research paper writing is an art. Keyword search should be as strategic as possible.

One should start brainstorming lists of potential keywords before even beginning searching. Think about the most important concepts related to research work. Ask, "What words would a source have to include to be truly valuable in a research paper?" Then consider synonyms for the important words.

It may take the discovery of only one important paper to steer in the right keyword direction because, in most databases, the keywords under which a research paper is abstracted are listed with the paper.

### **Numerical Methods**

Numerical methods used should be transparent and, where appropriate, supported by references.

### **Abbreviations**

Authors must list all the abbreviations used in the paper at the end of the paper or in a separate table before using them.

### **Formulas and equations**

Authors are advised to submit any mathematical equation using either MathJax, KaTeX, or LaTeX, or in a very high-quality image.

### **Tables, Figures, and Figure Legends**

Tables: Tables should be cautiously designed, uncrowned, and include only essential data. Each must have an Arabic number, e.g., Table 4, a self-explanatory caption, and be on a separate sheet. Authors must submit tables in an editable format and not as images. References to these tables (if any) must be mentioned accurately.





## Figures

Figures are supposed to be submitted as separate files. Always include a citation in the text for each figure using Arabic numbers, e.g., Fig. 4. Artwork must be submitted online in vector electronic form or by emailing it.

### PREPARATION OF ELETRONIC FIGURES FOR PUBLICATION

Although low-quality images are sufficient for review purposes, print publication requires high-quality images to prevent the final product being blurred or fuzzy. Submit (possibly by e-mail) EPS (line art) or TIFF (halftone/ photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Avoid using pixel-oriented software. Scans (TIFF only) should have a resolution of at least 350 dpi (halftone) or 700 to 1100 dpi (line drawings). Please give the data for figures in black and white or submit a Color Work Agreement form. EPS files must be saved with fonts embedded (and with a TIFF preview, if possible).

For scanned images, the scanning resolution at final image size ought to be as follows to ensure good reproduction: line art: >650 dpi; halftones (including gel photographs): >350 dpi; figures containing both halftone and line images: >650 dpi.

Color charges: Authors are advised to pay the full cost for the reproduction of their color artwork. Hence, please note that if there is color artwork in your manuscript when it is accepted for publication, we would require you to complete and return a Color Work Agreement form before your paper can be published. Also, you can email your editor to remove the color fee after acceptance of the paper.

### TIPS FOR WRITING A GOOD QUALITY MEDICAL RESEARCH PAPER

**1. Choosing the topic:** In most cases, the topic is selected by the interests of the author, but it can also be suggested by the guides. You can have several topics, and then judge which you are most comfortable with. This may be done by asking several questions of yourself, like "Will I be able to carry out a search in this area? Will I find all necessary resources to accomplish the search? Will I be able to find all information in this field area?" If the answer to this type of question is "yes," then you ought to choose that topic. In most cases, you may have to conduct surveys and visit several places. Also, you might have to do a lot of work to find all the rises and falls of the various data on that subject. Sometimes, detailed information plays a vital role, instead of short information. Evaluators are human: The first thing to remember is that evaluators are also human beings. They are not only meant for rejecting a paper. They are here to evaluate your paper. So present your best aspect.

**2. Think like evaluators:** If you are in confusion or getting demotivated because your paper may not be accepted by the evaluators, then think, and try to evaluate your paper like an evaluator. Try to understand what an evaluator wants in your research paper, and you will automatically have your answer. Make blueprints of paper: The outline is the plan or framework that will help you to arrange your thoughts. It will make your paper logical. But remember that all points of your outline must be related to the topic you have chosen.

**3. Ask your guides:** If you are having any difficulty with your research, then do not hesitate to share your difficulty with your guide (if you have one). They will surely help you out and resolve your doubts. If you can't clarify what exactly you require for your work, then ask your supervisor to help you with an alternative. He or she might also provide you with a list of essential readings.

**4. Use of computer is recommended:** As you are doing research in the field of medical research then this point is quite obvious. Use right software: Always use good quality software packages. If you are not capable of judging good software, then you can lose the quality of your paper unknowingly. There are various programs available to help you which you can get through the internet.

**5. Use the internet for help:** An excellent start for your paper is using Google. It is a wondrous search engine, where you can have your doubts resolved. You may also read some answers for the frequent question of how to write your research paper or find a model research paper. You can download books from the internet. If you have all the required books, place importance on reading, selecting, and analyzing the specified information. Then sketch out your research paper. Use big pictures: You may use encyclopedias like Wikipedia to get pictures with the best resolution. At Global Journals, you should strictly follow here.



**6. Bookmarks are useful:** When you read any book or magazine, you generally use bookmarks, right? It is a good habit which helps to not lose your continuity. You should always use bookmarks while searching on the internet also, which will make your search easier.

**7. Revise what you wrote:** When you write anything, always read it, summarize it, and then finalize it.

**8. Make every effort:** Make every effort to mention what you are going to write in your paper. That means always have a good start. Try to mention everything in the introduction—what is the need for a particular research paper. Polish your work with good writing skills and always give an evaluator what he wants. Make backups: When you are going to do any important thing like making a research paper, you should always have backup copies of it either on your computer or on paper. This protects you from losing any portion of your important data.

**9. Produce good diagrams of your own:** Always try to include good charts or diagrams in your paper to improve quality. Using several unnecessary diagrams will degrade the quality of your paper by creating a hodgepodge. So always try to include diagrams which were made by you to improve the readability of your paper. Use of direct quotes: When you do research relevant to literature, history, or current affairs, then use of quotes becomes essential, but if the study is relevant to science, use of quotes is not preferable.

**10. Use proper verb tense:** Use proper verb tenses in your paper. Use past tense to present those events that have happened. Use present tense to indicate events that are going on. Use future tense to indicate events that will happen in the future. Use of wrong tenses will confuse the evaluator. Avoid sentences that are incomplete.

**11. Pick a good study spot:** Always try to pick a spot for your research which is quiet. Not every spot is good for studying.

**12. Know what you know:** Always try to know what you know by making objectives, otherwise you will be confused and unable to achieve your target.

**13. Use good grammar:** Always use good grammar and words that will have a positive impact on the evaluator; use of good vocabulary does not mean using tough words which the evaluator has to find in a dictionary. Do not fragment sentences. Eliminate one-word sentences. Do not ever use a big word when a smaller one would suffice.

Verbs have to be in agreement with their subjects. In a research paper, do not start sentences with conjunctions or finish them with prepositions. When writing formally, it is advisable to never split an infinitive because someone will (wrongly) complain. Avoid clichés like a disease. Always shun irritating alliteration. Use language which is simple and straightforward. Put together a neat summary.

**14. Arrangement of information:** Each section of the main body should start with an opening sentence, and there should be a changeover at the end of the section. Give only valid and powerful arguments for your topic. You may also maintain your arguments with records.

**15. Never start at the last minute:** Always allow enough time for research work. Leaving everything to the last minute will degrade your paper and spoil your work.

**16. Multitasking in research is not good:** Doing several things at the same time is a bad habit in the case of research activity. Research is an area where everything has a particular time slot. Divide your research work into parts, and do a particular part in a particular time slot.

**17. Never copy others' work:** Never copy others' work and give it your name because if the evaluator has seen it anywhere, you will be in trouble. Take proper rest and food: No matter how many hours you spend on your research activity, if you are not taking care of your health, then all your efforts will have been in vain. For quality research, take proper rest and food.

**18. Go to seminars:** Attend seminars if the topic is relevant to your research area. Utilize all your resources.

**19. Refresh your mind after intervals:** Try to give your mind a rest by listening to soft music or sleeping in intervals. This will also improve your memory. Acquire colleagues: Always try to acquire colleagues. No matter how sharp you are, if you acquire colleagues, they can give you ideas which will be helpful to your research.



**20. Think technically:** Always think technically. If anything happens, search for its reasons, benefits, and demerits. Think and then print: When you go to print your paper, check that tables are not split, headings are not detached from their descriptions, and page sequence is maintained.

**21. Adding unnecessary information:** Do not add unnecessary information like "I have used MS Excel to draw graphs." Irrelevant and inappropriate material is superfluous. Foreign terminology and phrases are not apropos. One should never take a broad view. Analogy is like feathers on a snake. Use words properly, regardless of how others use them. Remove quotations. Puns are for kids, not grunt readers. Never oversimplify: When adding material to your research paper, never go for oversimplification; this will definitely irritate the evaluator. Be specific. Never use rhythmic redundancies. Contractions shouldn't be used in a research paper. Comparisons are as terrible as clichés. Give up ampersands, abbreviations, and so on. Remove commas that are not necessary. Parenthetical words should be between brackets or commas. Understatement is always the best way to put forward earth-shaking thoughts. Give a detailed literary review.

**22. Report concluded results:** Use concluded results. From raw data, filter the results, and then conclude your studies based on measurements and observations taken. An appropriate number of decimal places should be used. Parenthetical remarks are prohibited here. Proofread carefully at the final stage. At the end, give an outline to your arguments. Spot perspectives of further study of the subject. Justify your conclusion at the bottom sufficiently, which will probably include examples.

**23. Upon conclusion:** Once you have concluded your research, the next most important step is to present your findings. Presentation is extremely important as it is the definite medium through which your research is going to be in print for the rest of the crowd. Care should be taken to categorize your thoughts well and present them in a logical and neat manner. A good quality research paper format is essential because it serves to highlight your research paper and bring to light all necessary aspects of your research.

## INFORMAL GUIDELINES OF RESEARCH PAPER WRITING

### **Key points to remember:**

- Submit all work in its final form.
- Write your paper in the form which is presented in the guidelines using the template.
- Please note the criteria peer reviewers will use for grading the final paper.

### **Final points:**

One purpose of organizing a research paper is to let people interpret your efforts selectively. The journal requires the following sections, submitted in the order listed, with each section starting on a new page:

*The introduction:* This will be compiled from reference matter and reflect the design processes or outline of basis that directed you to make a study. As you carry out the process of study, the method and process section will be constructed like that. The results segment will show related statistics in nearly sequential order and direct reviewers to similar intellectual paths throughout the data that you gathered to carry out your study.

### **The discussion section:**

This will provide understanding of the data and projections as to the implications of the results. The use of good quality references throughout the paper will give the effort trustworthiness by representing an alertness to prior workings.

Writing a research paper is not an easy job, no matter how trouble-free the actual research or concept. Practice, excellent preparation, and controlled record-keeping are the only means to make straightforward progression.

### **General style:**

Specific editorial column necessities for compliance of a manuscript will always take over from directions in these general guidelines.

**To make a paper clear:** Adhere to recommended page limits.



### *Mistakes to avoid:*

- Insertion of a title at the foot of a page with subsequent text on the next page.
- Separating a table, chart, or figure—confine each to a single page.
- Submitting a manuscript with pages out of sequence.
- In every section of your document, use standard writing style, including articles ("a" and "the").
- Keep paying attention to the topic of the paper.
- Use paragraphs to split each significant point (excluding the abstract).
- Align the primary line of each section.
- Present your points in sound order.
- Use present tense to report well-accepted matters.
- Use past tense to describe specific results.
- Do not use familiar wording; don't address the reviewer directly. Don't use slang or superlatives.
- Avoid use of extra pictures—include only those figures essential to presenting results.

### **Title page:**

Choose a revealing title. It should be short and include the name(s) and address(es) of all authors. It should not have acronyms or abbreviations or exceed two printed lines.

**Abstract:** This summary should be two hundred words or less. It should clearly and briefly explain the key findings reported in the manuscript and must have precise statistics. It should not have acronyms or abbreviations. It should be logical in itself. Do not cite references at this point.

An abstract is a brief, distinct paragraph summary of finished work or work in development. In a minute or less, a reviewer can be taught the foundation behind the study, common approaches to the problem, relevant results, and significant conclusions or new questions.

Write your summary when your paper is completed because how can you write the summary of anything which is not yet written? Wealth of terminology is very essential in abstract. Use comprehensive sentences, and do not sacrifice readability for brevity; you can maintain it succinctly by phrasing sentences so that they provide more than a lone rationale. The author can at this moment go straight to shortening the outcome. Sum up the study with the subsequent elements in any summary. Try to limit the initial two items to no more than one line each.

*Reason for writing the article—theory, overall issue, purpose.*

- Fundamental goal.
- To-the-point depiction of the research.
- Consequences, including definite statistics—if the consequences are quantitative in nature, account for this; results of any numerical analysis should be reported. Significant conclusions or questions that emerge from the research.

### **Approach:**

- Single section and succinct.
- An outline of the job done is always written in past tense.
- Concentrate on shortening results—limit background information to a verdict or two.
- Exact spelling, clarity of sentences and phrases, and appropriate reporting of quantities (proper units, important statistics) are just as significant in an abstract as they are anywhere else.

### **Introduction:**

The introduction should "introduce" the manuscript. The reviewer should be presented with sufficient background information to be capable of comprehending and calculating the purpose of your study without having to refer to other works. The basis for the study should be offered. Give the most important references, but avoid making a comprehensive appraisal of the topic. Describe the problem visibly. If the problem is not acknowledged in a logical, reasonable way, the reviewer will give no attention to your results. Speak in common terms about techniques used to explain the problem, if needed, but do not present any particulars about the protocols here.



*The following approach can create a valuable beginning:*

- Explain the value (significance) of the study.
- Defend the model—why did you employ this particular system or method? What is its compensation? Remark upon its appropriateness from an abstract point of view as well as pointing out sensible reasons for using it.
- Present a justification. State your particular theory(-ies) or aim(s), and describe the logic that led you to choose them.
- Briefly explain the study's tentative purpose and how it meets the declared objectives.

#### **Approach:**

Use past tense except for when referring to recognized facts. After all, the manuscript will be submitted after the entire job is done. Sort out your thoughts; manufacture one key point for every section. If you make the four points listed above, you will need at least four paragraphs. Present surrounding information only when it is necessary to support a situation. The reviewer does not desire to read everything you know about a topic. Shape the theory specifically—do not take a broad view.

As always, give awareness to spelling, simplicity, and correctness of sentences and phrases.

#### **Procedures (methods and materials):**

This part is supposed to be the easiest to carve if you have good skills. A soundly written procedures segment allows a capable scientist to replicate your results. Present precise information about your supplies. The suppliers and clarity of reagents can be helpful bits of information. Present methods in sequential order, but linked methodologies can be grouped as a segment. Be concise when relating the protocols. Attempt to give the least amount of information that would permit another capable scientist to replicate your outcome, but be cautious that vital information is integrated. The use of subheadings is suggested and ought to be synchronized with the results section.

When a technique is used that has been well-described in another section, mention the specific item describing the way, but draw the basic principle while stating the situation. The purpose is to show all particular resources and broad procedures so that another person may use some or all of the methods in one more study or referee the scientific value of your work. It is not to be a step-by-step report of the whole thing you did, nor is a methods section a set of orders.

#### **Materials:**

*Materials may be reported in part of a section or else they may be recognized along with your measures.*

#### **Methods:**

- Report the method and not the particulars of each process that engaged the same methodology.
- Describe the method entirely.
- To be succinct, present methods under headings dedicated to specific dealings or groups of measures.
- Simplify—detail how procedures were completed, not how they were performed on a particular day.
- If well-known procedures were used, account for the procedure by name, possibly with a reference, and that's all.

#### **Approach:**

It is embarrassing to use vigorous voice when documenting methods without using first person, which would focus the reviewer's interest on the researcher rather than the job. As a result, when writing up the methods, most authors use third person passive voice.

Use standard style in this and every other part of the paper—avoid familiar lists, and use full sentences.

#### **What to keep away from:**

- Resources and methods are not a set of information.
- Skip all descriptive information and surroundings—save it for the argument.
- Leave out information that is immaterial to a third party.



**Results:**

The principle of a results segment is to present and demonstrate your conclusion. Create this part as entirely objective details of the outcome, and save all understanding for the discussion.

The page length of this segment is set by the sum and types of data to be reported. Use statistics and tables, if suitable, to present consequences most efficiently.

You must clearly differentiate material which would usually be incorporated in a study editorial from any unprocessed data or additional appendix matter that would not be available. In fact, such matters should not be submitted at all except if requested by the instructor.

**Content:**

- Sum up your conclusions in text and demonstrate them, if suitable, with figures and tables.
- In the manuscript, explain each of your consequences, and point the reader to remarks that are most appropriate.
- Present a background, such as by describing the question that was addressed by creation of an exacting study.
- Explain results of control experiments and give remarks that are not accessible in a prescribed figure or table, if appropriate.
- Examine your data, then prepare the analyzed (transformed) data in the form of a figure (graph), table, or manuscript.

**What to stay away from:**

- Do not discuss or infer your outcome, report surrounding information, or try to explain anything.
- Do not include raw data or intermediate calculations in a research manuscript.
- Do not present similar data more than once.
- A manuscript should complement any figures or tables, not duplicate information.
- Never confuse figures with tables—there is a difference.

**Approach:**

As always, use past tense when you submit your results, and put the whole thing in a reasonable order.

Put figures and tables, appropriately numbered, in order at the end of the report.

If you desire, you may place your figures and tables properly within the text of your results section.

**Figures and tables:**

If you put figures and tables at the end of some details, make certain that they are visibly distinguished from any attached appendix materials, such as raw facts. Whatever the position, each table must be titled, numbered one after the other, and include a heading. All figures and tables must be divided from the text.

**Discussion:**

The discussion is expected to be the trickiest segment to write. A lot of papers submitted to the journal are discarded based on problems with the discussion. There is no rule for how long an argument should be.

Position your understanding of the outcome visibly to lead the reviewer through your conclusions, and then finish the paper with a summing up of the implications of the study. The purpose here is to offer an understanding of your results and support all of your conclusions, using facts from your research and generally accepted information, if suitable. The implication of results should be fully described.

Infer your data in the conversation in suitable depth. This means that when you clarify an observable fact, you must explain mechanisms that may account for the observation. If your results vary from your prospect, make clear why that may have happened. If your results agree, then explain the theory that the proof supported. It is never suitable to just state that the data approved the prospect, and let it drop at that. Make a decision as to whether each premise is supported or discarded or if you cannot make a conclusion with assurance. Do not just dismiss a study or part of a study as "uncertain."





Research papers are not acknowledged if the work is imperfect. Draw what conclusions you can based upon the results that you have, and take care of the study as a finished work.

- You may propose future guidelines, such as how an experiment might be personalized to accomplish a new idea.
- Give details of all of your remarks as much as possible, focusing on mechanisms.
- Make a decision as to whether the tentative design sufficiently addressed the theory and whether or not it was correctly restricted. Try to present substitute explanations if they are sensible alternatives.
- One piece of research will not counter an overall question, so maintain the large picture in mind. Where do you go next? The best studies unlock new avenues of study. What questions remain?
- Recommendations for detailed papers will offer supplementary suggestions.

**Approach:**

When you refer to information, differentiate data generated by your own studies from other available information. Present work done by specific persons (including you) in past tense.

Describe generally acknowledged facts and main beliefs in present tense.

## THE ADMINISTRATION RULES

Administration Rules to Be Strictly Followed before Submitting Your Research Paper to Global Journals Inc.

*Please read the following rules and regulations carefully before submitting your research paper to Global Journals Inc. to avoid rejection.*

*Segment draft and final research paper:* You have to strictly follow the template of a research paper, failing which your paper may get rejected. You are expected to write each part of the paper wholly on your own. The peer reviewers need to identify your own perspective of the concepts in your own terms. Please do not extract straight from any other source, and do not rephrase someone else's analysis. Do not allow anyone else to proofread your manuscript.

*Written material:* You may discuss this with your guides and key sources. Do not copy anyone else's paper, even if this is only imitation, otherwise it will be rejected on the grounds of plagiarism, which is illegal. Various methods to avoid plagiarism are strictly applied by us to every paper, and, if found guilty, you may be blacklisted, which could affect your career adversely. To guard yourself and others from possible illegal use, please do not permit anyone to use or even read your paper and file.



CRITERION FOR GRADING A RESEARCH PAPER (COMPILATION)  
BY GLOBAL JOURNALS

Please note that following table is only a Grading of "Paper Compilation" and not on "Performed/Stated Research" whose grading solely depends on Individual Assigned Peer Reviewer and Editorial Board Member. These can be available only on request and after decision of Paper. This report will be the property of Global Journals.

Topics	Grades		
	A-B	C-D	E-F
<i>Abstract</i>	Clear and concise with appropriate content, Correct format. 200 words or below	Unclear summary and no specific data, Incorrect form Above 200 words	No specific data with ambiguous information Above 250 words
<i>Introduction</i>	Containing all background details with clear goal and appropriate details, flow specification, no grammar and spelling mistake, well organized sentence and paragraph, reference cited	Unclear and confusing data, appropriate format, grammar and spelling errors with unorganized matter	Out of place depth and content, hazy format
<i>Methods and Procedures</i>	Clear and to the point with well arranged paragraph, precision and accuracy of facts and figures, well organized subheads	Difficult to comprehend with embarrassed text, too much explanation but completed	Incorrect and unorganized structure with hazy meaning
<i>Result</i>	Well organized, Clear and specific, Correct units with precision, correct data, well structuring of paragraph, no grammar and spelling mistake	Complete and embarrassed text, difficult to comprehend	Irregular format with wrong facts and figures
<i>Discussion</i>	Well organized, meaningful specification, sound conclusion, logical and concise explanation, highly structured paragraph reference cited	Wordy, unclear conclusion, spurious	Conclusion is not cited, unorganized, difficult to comprehend
<i>References</i>	Complete and correct format, well organized	Beside the point, Incomplete	Wrong format and structuring



# INDEX

---

---

## **A**

Aminotransferase · 22

---

## **B**

Bioflavonoids · 25

---

## **D**

Diabetogenic · 25  
Dipotassium · 19  
Dyskeratosis · 8  
Dyslipidemia · 25

---

## **E**

Epigastrica · 5

---

## **G**

Glycaemic · 14

---

## **H**

Hemicellulose · 19  
Hyperglycaemia · 30  
Hyperkeratotic · 8, 9, 10

---

## **K**

Krioaplikatsiya · 2

---

## **L**

Lipotoxicity · 25  
Lymphorrhea · 2, 5, 6

---

## **P**

Pachyonychia · 8, 11  
Papillomatosis · 2  
Pilosebaceous · 8  
Polyphagia · 24



save our planet




# Global Journal of Medical Research

---

Visit us on the Web at [www.GlobalJournals.org](http://www.GlobalJournals.org) | [www.MedicalResearchJournal.org](http://www.MedicalResearchJournal.org)  
or email us at [helpdesk@globaljournals.org](mailto:helpdesk@globaljournals.org)

ISSN 9755896



© Global Journals